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Abbreviation    Full name 
 
4-HPR     N- (4-Hydroxyphenyl)-retinamide;  
Ferentinide 
 
5-FU      5-fluorouracil 
 
AUC      Area under the plasma concentration-time  
curve 
 
BCC      Basal cell carcinoma 
 
BSA      Bovine serum albumin 
 
CD      Cyclodextrin 
 
 DMBCD    heptakis (2,6-di-O-methyl)--cyclodextrin 
 
HPBCD    Hydroxypropyl--cyclodextrin 
 
RMBCD    Randomly methylated--cyclodextrin 
 
SBEBCD    Sulfobutyl ether--cyclodextrin 
 
CDDP      Cisplatin 
 
Cl      Clearance 
 
Cmax      Maximum concentration 
 
DMEM     Dulbecco’s modified Eagle’s medium 
 
DMSO     Dimethyl sulphoxide 
 
DSC      Differential scanning calorimetry 
 
ECM      Extracellular matrix 
 
F      Oral bioavailability 
 
FBS      Fetal bovine serum 
 
 IV 
FDA      Fluorescein diacetate 
 
IC50      50% inhibitory concentration 
 
IR      Infrared spectroscopy 
 
K10 Elimination rate constant from the 
central compartment  
            
K12 Distribution rate constant from the 
central compartment to the peripheral 
compartment  
 
K21 Distribution rate constant from the 
peripheral compartment to the central 
compartment  
 
MMP      Matrix metalloproteinase 
 
PBS      Phosphate-buffered saline 
 
RA      Retinoid acid 
  
 ATRA     All-tans-retinoic acid; tretinoin 
 
 9-cis-RA    9-cis-retinoic acid 
 
 13-cis-RA    13-cis-retinoic acid 
 
RAR      Retinoic acid receptor 
 
RARE      Retinoic acid response element 
 
RXR      Retinoid X receptor 
 
RXRE      Retinoid X response element 
 
SCC      Squamous cell carcinoma 
 
SD      Standard deviation 
 
SDS-PAGE     SDS-polyacrylamide gel electrophoresis 
 
SEM      Scanning electron microscopy 
 
SI      Survival index 
 V
 
Vc      Volume of central compartment 
 
Vss      Volume of distribution at steady state 
 
XRD       X-ray diffractometry 
 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENT             I        
       
ABBREVIATION LIST          III 
           
TABLE OF CONTENTS          VI  
 
SUMMARY                                     XI 
 
LIST OF TABLES              XIII 
 
LIST OF FIGURES             XV 
 




CHAPTER 1. INTRODUCTION                                     1 
 
1.1 Retinoids                                                 1 
 
1.1.1 Chemical structures and physicochemical properties   1          
of retinoids 
 
1.1.2 The nuclear retinoid receptors                        6                                
 
1.1.3 Retinoids in chemoprevention                          11 
 
1.1.4 Retinoids in cancer therapy                            14 
 
1.2 Melanoma                                                  20 
 
1.3 Pharmaceutical applications of cyclodextrin             26 
 
1.3.1 Chemical structure and physicochemical properties    28 
of cyclodextrin 
 
1.3.2 Cyclodextrin inclusion complexes                      35 
 
1.3.2.1 Evaluating inclusion complexation                  37 
  
 VI
1.3.2.2     Factors affecting complexation                  41 
 
1.3.2.3     Benefits of complexation                        43 
 
1.3.2.4     Preparation and characterization of             45 
                   inclusion complexes 
 
1.3.3     Cyclodextrins in various pharmaceutical           46 




CHAPTER 2. HYPOTHESIS AND OBJECTIVES    51 
 
2.1 Investigation of effects of retinoids on murine     51       
melanoma cells (B16-F10 cells) 
 
2.2 Development of cyclodextrin-based formulation        56 
               of acitretin and 13-cis-RA 
 
2.3 Pharmacokinetic studies of CD-based formulation   60 




CHAPTER 3. EVALUATION OF RETINOID EFFECTS ON  
MURINE MELANOMA CELLS      62 
       
3.1         Materials and Methods       62 
 
3.1.1 Materials                   62 
 
3.1.2 Cell culture conditions      63 
 
3.1.3 Animals         63 
 
3.1.4 Cell proliferation study      63 
 
3.1.5 Combination chemotherapy studies    64 
 
3.1.6 In vitro cell invasion study      65 
 
3.1.7 Western blot analysis                 66 
 




3.1.9 Effect of retinoids and cisplatin combination on               67 
               tumor development in C57BL/6J mice injected with  
               B16F10 melanoma cells 
 
3.1.10 Statistical analysis       68 
 
3.2 Results                                                                                                                  69 
 
3.2.1 Cell proliferation study       69 
 
3.2.2 Combination chemotherapy studies     69 
 
3.2.3 Effect of retinoids on the invasion of B16-F10 cells   76 
3.2.4 Western blot analysis of MMP-9      79 
 
3.2.5 Effect of retinoids on experimental lung metastasis in mice         80 
3.2.6 Effect of retinoid and cisplatin combination on tumor                  84 
               development in mice injected with B16F10 melanoma cells 
 
3.3 Discussion          87 
 




CHAPTER 4. DEVELOPMENT OF CYCLODEXTRIN BASED   
FORMULATIONS OF RETINOIDS: ACITRETIN AND 13-CIS-
RETINOIC ACID                 92 
 
4.1          Materials         92 
 
4.2          Apparatus         93 
 
4.3          Methods         94 
 
4.3.1 Special precautions       94 
 
4.3.2 Phase-solubility study      94 
 
4.3.3 Photostability study       95 
 
 VIII
4.3.4 Preparation of the solid drug/CD complexes   96 
 
4.3.5 Infrared Spectroscopy (IR)      97 
 
4.3.6 Differential Scanning Calorimetry (DSC)    97 
 
4.3.7 Scanning Electron Microscopy (SEM)    97 
 
4.3.8 X-ray Diffractometry (XRD)     97 
 
4.3.9 Molecular Modeling       98 
 
4.4          Results and Discussion       99 
 
4.4.1 Phase-solubility study      99 
 
4.4.2 Photostability study       110 
 
4.4.3 Physicochemical characterization     115 
 
4.4.3.1    IR spectra                   115 
 
4.4.3.2   Differential scanning calorimetry (DSC)               118 
 
4.4.3.3    Scanning electron microscopy (SEM)               121 
 
4.4.3.4    X-ray diffractometry (XRD)                123 
 
4.4.4 Molecular modeling       125 
       




CHAPTER 5. BIOPHARMACEUTICS OF CYCLODEXTRIN- 
BASED FORMULATIONS OF ACITRETIN IN SPRAGUE- 
DAWLEY RATS         130 
 
5.1          Special precautions       130 
 
5.2          Materials         130 
 
5.3          Analytical  procedures       131 
 
5.3.1 Measurement of acitretin in plasma    131 
 IX
 
5.3.2 Measurement of the total concentration of acitretin  132 
              and its β-glucuronide conjugated metabolite in bile 
 
5.4        Preparation of dosing solutions      133 
 
5.5        Animals         134 
 
5.6        Pharmacokinetic analysis       136 
 
5.7        Statistical analysis        137 
 
5.8        Results         138 
 
5.8.1 Intravenous administration study     138 
 
5.8.2 Biliary excretion of acitretin     141 
 
5.8.3 Oral administration study      145 
 
5.9        Discussion         149 
 




CHAPTER 6. CONCLUSIONS & FUTURE STUDIES  158 
 
6.1          Conclusions          158 
 
















Retinoids belong to a class of natural and synthetic compounds showing similar 
biological activities to Vitamin A (retinol). Retinoids control cell proliferation and 
differentiation of many epithelial tissues. These compounds are mostly insoluble in 
water and are light sensitive.  
Cyclodextrins (CDs), cyclic oligosaccharides derived from starch, have been used 
extensively to increase the aqueous solubility, stability and bioavailability of drugs 
by formation of inclusion complexes with drugs.  
Malignant melanoma is a common type of cancer with high mortality rate. 
Metastases are the major cause of death in affected patients. Alternative approaches 
for therapy of disseminated malignant melanoma are urgently needed. 
 
Purposes 
The purposes of this project were to investigate the effects of retinoids on murine 
melanoma cells, and to develop cyclodextrin-based formulations of retinoids to 
improve their solubility, photostability and bioavailability. 
 
Methods 
The anti-proliferation and anti-metastatic effects of retinoids were tested in the 
melanoma B16-F10 cell culture model and the mouse tumor models. 
 XII 
Phase solubility and photo stability studies were performed to characterize the 
effects of CDs on retinoids. Molecular modeling was carried out to supplement the 
experimental results. Pharmacokinetic properties of the newly developed CD-based 
formulations were studied in Sprague-Dawley rats.  
 
Results 
The anti-proliferation and anti-metastatic effects of retinoids were confirmed in 
B16-F10 cells and the experimental lung metastasis model.  
The aqueous solubility and photostability of acitretin and 13-cis-RA were 
dramatically improved by inclusion into CDs. Molecular modeling predictions were 
consistent with the findings from the phase solubility studies.  
CD-based formulation of acitretin could improve its oral bioavailability and 
decrease the variation of its oral pharmacokinetics. The pharmacokinetic property 
was linear after intravenous dosing. The primary route of elimination for acitretin 




The CDs based formulations of acitretin and 13-cis-RA could offer some advantages 
over current capsule dosage form. CD could be a promising excipient for the 
formulation of retinoids. The potential of retinoids on the treatment of melanoma 
was demonstrated by current studies. However, these findings have to be confirmed 
by further studies.  
 XIII 
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Chapter 1. Introduction 
 
 
1.1      Retinoids 
         The term “retinoid” was first introduced by Sporn and their co-workers in 1976 
(Sporn et al., 1976). It is referred to as a class of natural and synthetic compounds 
showing similar biological activities to Vitamin A (retinol). Retinoids control cell 
proliferation and differentiation in many epithelial tissues (Sporn et al., 1976). Based on 
these properties, retinoids were introduced to dermatology about twenty years ago 
(Orfanos, 1980) and have been increasingly used for topical and systemic treatment of 
skin disorders such as psoriasis, acne and acne related dermatoses, keratotic 
genodermatoses, and also for therapy and/or chemoprevention of skin cancer and other 
neoplasia . 
 
1.1.1 Chemical structures and physicochemical properties of retinoids 
         Structurally, retinoids have been defined as a class of compounds consisting of four 
isoprenoid units (H2C=C(CH3)-CH=CH2) joined in a head to tail manner (Barua and Furr, 
1998). The retinoid molecule can be divided into three parts: a trimethylated cyclohexene 
ring, a conjugated tetraene side chain, and a polar carbonoxygen functional group. In the 
search for more effective and less toxic compounds, all 3 portions of the retinoid 
molecule have been chemically modified resulting in three generations of compounds – 
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nonaromatic, monoaromatic and polyaromatic retinoids (Orfanos et al., 1985; Shalita et 
al., 1996) (Table1.1). Among these retinoids, all-trans-retinol (vitamin A), all-trans-
retinal, all-trans-retinoic acid (ATRA), 9-cis-retinoic acid (9-cis-RA), 13-cis-retinoic acid 
(13-cis-RA) are naturally occurring retinoids, while acitretin, etretinate, fenretinide 
(4HPR), adapalene, and tazarotene are synthetic retinoids (Barua and Furr, 1998; Roos et 
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Table 1.1.1 Three generation of retinoidsa  
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Table 1.1.1 Three generation of retinoids (continued) 
Retinoid Structure Remarks 














































a. The information of this table was obtained from Roos et al., 1998. 
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        Commercial preparations of retinoic acid, retinyl palmitate, retinaldehyde, and 
retinol are pale-yellow to yellow crystalline or amorphous solids. Retinol and its esters 
are low melting compounds (melting point around 60 °C), and they may turn to oil at 
room temperature. Because of the presence of conjugated double bonds of the isoprenoid 
chain, retinoids in general are unstable compounds. They are susceptible to oxidation, 
isomerization, photodegradation. Consequently, naturally occurring retinoids are 
extremely labile. Some retinoids are very irritating to the skin and some are highly 
teratogenic. Hence when large amounts of retinoids are handled, adequate care should be 
taken to avoid solid particles or solutions coming into contact with the body.  
 
         Retinoids are poorly soluble in water as a result of the presence of a large 
hydrophobic moiety in them. Quantitative data on the aqueous solubility of retinoids are 
scarce. The solubility of individual retinoids in organic solvents depends on the terminal 
group of the side chain. Dimethylsulfoxide is often used to deliver retinoids into cell 
culture systems; it is appropriate for this use, but its low volatility prevents its use when 
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1.1.2 The nuclear retinoid receptors 
          Retinoids exert most of their effects by binding to or activating specific receptors 
and modulating the expression of retinoid target genes. The nuclear retinoid receptors are 
members of steroid/thyroid hormone superfamily receptors (Evans, 1988) with which 
they share common structural and functional properties. Two types of nuclear receptors, 
retinoic acid receptors (RARs) and retinoid X receptors (RXRs), and their respective α, β, 
and γ subtypes, have been identified (Giguere et al., 1987; Petkovich et al., 1987; 
Benbrook et al., 1988; Brand et al., 1988; Krust et al., 1989). The receptor subtypes and 
isoforms are expressed in a developmental and tissue specific manner, which suggests 
that each of them may have specific effects in the regulation of developmental and cell 
type or tissue specific biological processes. Boylan and his coworkers (1995) have 
recently reported that the inducibility of a number of retinoid target genes is differentially 
affected by disruption of either the RARα or RARγ gene suggesting that these receptors 
are not redundant, but each receptor regulates the expression of a set of unique genes. 
These receptors exhibit distinct ligand binding properties; the RARs bind ATRA and 9-
cis-RA, whereas the RXRs bind 9-cis-RA selectively. In addition, the so-called RXR 
selective retinoids that only bind RXRs with high affinity have been discovered 
(Lehmann et al., 1992), while natural high-affinity ligands selective for RXR have not 
been found so far.  
 
            RAR and RXR act as modulators of gene transcription and consisting of 6 various 
domains which are designated A to F (as shown in Figure 1.1). The major functional 
domains include DNA binding domain C and ligand binding domain E. Important 
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subdomains are those responsible for transactivation (AFs1 and 2) and for dimerization 
(both located within the E domain) ( Lee et al., 1993; Warrell et al., 1993). The DNA 
binding domain recognizes and binds DNA sequences within promoter regions of target 
genes which are referred to as retinoic acid and retinoid X response elements (RARE and 
RXRE, respectively) (Lee et al., 1993). The ligand binding domain occupies the same 
region of the receptor as the ligand dependent trans-activation function. This latter 
structure appears to be activated by the process of ligand binding and consequent 
conformational changes and serves to modulate gene transcription (Nagpal et al., 1992). 
To convert the retinoid signal into transcriptional activation of a gene, the RARs function 
as heterodimers with RXRs. Only the RXR-RAR heterodimers were found to bind 
effectively to their DNA recognition sequences (Zhang et al., 1992). While RARs may 
only dimerized with RXRs, RXRs can homodimerize as well as dimerize with Vitamin D, 
thyroid hormone and a number of orphan receptors (Warrell et al., 1993). Thus, 
activation of RXRs can result in the signaling among numerous pathways. The RARs 
have been found to bind to a number of RAREs which, in general, have been found to be 
direct repeats of AGGTCA (Mangelsdorf et al., 1994). RXR-RXR homodimers bind to 
RXREs (5’-AGGTCA-3’) in which the half sites are separated by a single base pair; more 
complex RXREs have also been identified (Xiao et al., 1995; Shago and Giguere, 1996). 
The DNA/receptor dimmer complex when bound to ligand results in a conformation 
change in the dimmer complex resulting in either gene transcriptional activation or 
repression and subsequent modulation of mRNA levels. 
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           b 
 
Figure 1.1.1 Retinoid nuclear receptors. (a) RAR/RXR functional domains and     
                     consensus sequences. (b) Structure of natural ligands (Modified from 
Fontana and Rishi, 2002) 
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           At cellular level, activation of the retinoid receptor can inhibit cell proliferation, 
induce differentiation and apoptosis in mesenchymal, neuroectodermal, haematopoietic 
and epithelial cells during normal development, as well as normal and transformed cells 
in tissue culture. However, the specific receptor that mediates these effects may differ 
from each cell line. Furthermore, the induction of apoptosis is related to cell growth and 
differentiation in various ways, depending on the cell type. For example, retinoids 
initially induce the human myeloid leukemia HL-60 cells to differentiate into neutrophils 
which subsequently undergo apoptosis (Martin et al., 1990). In contrast, retinoids can 
induce differentiation and apoptosis concurrently as in F9 embryonal carcinoma cells 
(Atencia et al., 1994), or can induce apoptosis without differentiation as in neuroblastoma 
cells (Piacentini et al., 1992). Moreover, retinoids can also inhibit growth and 
differentiation in head and neck squamous cancer cell lines (Kabbout et al., 2004; Kudaro 
et al., 2005), and at the same time induce apoptosis in these cell lines (Oridate et al., 
1996).  
     
         The isolation and crystallization of the various classes and subclasses of retinoid 
nuclear receptors allowed the synthesis of both class and subtype-selective retinoids. 
RARα, β, and γ, as well as RXR selective retinoids have been reported by a number of 
groups (Bernard BA et al., 1992; Dawson et al., 1995). These selective retinoids allow 
elucidation of the biological roles of the individual retinoid receptors. These retinoids 
may also be promising therapeutic agents with less side effects as they can reduce side 
effects normally associated with natural retinoids while keeping their efficacy. 
Compounds selectively activating RAR pathways were first identified (Crettaz et al., 
Chapter 1. Introduction      
 10
1990; Lehmann et al., 1991; Graupner et al., 1991). Among these compounds, fenretinide 
or 4-hydroxyphenylretinamide (4-HPR) inhibits proliferation of cancer cells and has been 
shown to selectively activate RARγ (Fanjul et al., 1996). This drug holds promise in 
clinical trials for chemoprevention and cancer treatment because of its low toxicity. 
RXR-selective compounds have proven to be effective for chemoprevention and 
treatment of cancer as well. For example, LGD 1069 is being used for the treatment of 
cutaneous T-cell lymphoma and is being evaluated in many clinical trials for treatment of 





                                         
                                      LGD 1069 (Targretin, Bexarotene) 
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1.1.3 Retinoids in chemoprevention 
           Many cancers develop as a result of exposure to carcinogens and cancer-
promoting agents in a multi-step process including both initiation and promotion. 
Chemoprevention entails the use of specific agents to suppress, reverse or block 
carcinogenesis and thereby prevents the development of primary or secondary primary 
cancers (Greenwald et al., 1995). It seems to be a promising approach for reducing 
cancer occurrence both in defined high-risk groups and in the general population. 
Retinoids are prime candidates for cancer chemoprevention since cancer is characterized 
by abnormal growth with a lack of differentiation, which could be modified by retinoids 
(Hong et al., 1995; Lippman et al., 1995). Much evidence supports the idea that retinoids 
can prevent cancer by inhibiting progression from premalignant to malignant stages 
(Chen et al., 1995; Tennenbaum et al., 1998). Numerous investigations have found a 
strong relationship between vitamin A and cancer development over the last couple of 
decades. Experimental animal model studies revealed that vitamin A deficiency was 
associated with a higher incidence of cancer and with increased susceptibility to chemical 
carcinogens (Moon et al., 1994). Further, epidemiological evidence indicated that 
individuals with lower vitamin A are at a higher risk of developing cancer (Hong and Itri, 
1994). These findings provided the basis for the use of retinoids in clinical cancer 
chemoprevention. Many clinical trials of retinoids as chemoprevention agents are in 
progress or have been completed. Most of these trials focus on individuals at an increased 
risk of developing cancer, such as patients with pre-malignant lesions or patients who 
have been successfully treated for an early-stage carcinoma and have high risks of 
developing a second primary cancer.  
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           Skin cancer is one of the most common cancers with a tremendous impact on 
morbidity, health and healthcare economics (Shouse and Day, 1993). A high skin cancer 
risk can result from inherited disorders such as xeroderma pigmentosum (abnormal repair 
of UV-induced DNA damage) or the nevoid basal cell carcinoma syndrome (tumor 
suppressor gene abnormality). Immunosuppression is another condition that can also 
result in an increased risk of subsequent malignancy such as skin cancer. This is a 
significant and common problem in post-transplantation patients who are chronically 
immunosuppressed. Results from several laboratory and clinical trials suggest that 
retinoids have skin cancer chemopreventive effects. In a phase III double blind, 
randomized study of Vitamin A versus placebo in patients with moderate to severe 
actinic keratosis, daily Vitamin A (25000 IU) reduced the risk of developing squamous 
cell carcinomas of the skin with no significant toxicity (Moon et al., 1997). In a 
prospective, controlled study, patients with xeroderma pigmentosum who were 
developing large numbers of skin cancer were treated with high dose (2mg/kg/day) of 
isotretinoin for 2 years (Kraemer et al., 1988). This regimen was effective in reducing the 
development of new skin cancer in most patients. The chemopreventive benefit persisted 
during therapy but appeared to be lost within 2-3 months post-treatment. This indicates 
that the retinoids act late in the course of events necessary to develop a malignancy. In 
chronically immunosuppressed post-transplantation patients, etretinate was associated 
with a large reduction in the incidence of squamous cell carcinoma (Kelly et al., 1991). 
Chemopreventive benefit of etretinate was lost quickly after the discontinuation of drug, 
which was similar to the observation in patients treated with isotretinoin. In a prospective, 
open randomized crossover trial, renal transplant patients were treated with acitretin 25 
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mg daily or on alternate days. The number of squamous cell carcinomas (SCC) observed 
in patients while on acitretin was significantly lower than that in the drug-free period (P = 
0.002) (George et al., 2002). Another study used 0.3mg/kg/day of acitretin in renal 
transplant patients over a 5-year period and found a significant reduction in the number of 
new skin tumor excised in most of patients during treatment compared to the same 
pretreatment interval (McKenna and Murphy, 1999). Since the benefit of retinoids 
chemoprevention is present only during the time of treatment, long-term therapy is 
usually necessary. Dosage of retinoids should be re-evaluated periodically because the 
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1.1.4 Retinoids in cancer therapy 
        Tumorigenesis results from many factors such as inherited and acquired genetic 
changes, chromosomal rearrangements, epigenetic phenomena and chemical 
carcinogenesis (Berglund et al., 2002; Carlton et al., 2002; Blagosklonny, 2005; 
Wijnhoven et al., 2005). Retinoids can interfere with these events at several levels as 
shown in Figure 1.1.3. Their principal known actions include induction of differentiation 
and/or apoptosis of tumor cells, inhibition of tumor promotion in chemically induced 
cancers. Due to their ability to regulate growth and induce differentiation throughout life, 
retinoids affect the growth of many tumor cell lines. 
         
         The use of retinoids in clinical cancer therapy has been extensively studied over the 
years and the best example is represented by the successful use of ATRA in the treatment 
of acute promyelocytic leukemia (APL), while 13-cis-RA is effective against juvenile 
chronic myelogenous leukemia and mycosis fungoides (cutaneous T-cell lymphoma) in 
clinical studies.  Chinese clinicians claimed an 85% complete remission rate in a report 
on 787 patients with APL (Chen et al., 1991). In the western world and Japan, 195 
patients out of 228 cases experienced complete remission, corresponding to 85.5% 
(Fenaux et al., 1992). The induction of complete remission by ATRA, followed by 
consolidation therapy with cytostatic agents such as daunomycin and cytosine 
arabinoside, produced a longer event-free survival than with chemotherapy alone (Fenaux 
et al., 1992). 
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          Various cancers other than APL are already being treated with retinoid-based 
therapies, and several are undergoing clinical evaluation (Table 1.1.2). For several 
carcinomas, more than one retinoid is being evaluated and many clinical studies are 
underway to assess their efficacy.  However, natural retinoids have shown limited 
efficacy in most solid malignancies. Furthermore, the reversible effect of retinoids 
requires prolonged treatments that are often associated with toxicity and the development 
of retinoid resistance. Thus, the use of retinoids alone to treat cancer or to prevent the 
onset of second tumors may not be optimal. Numerous studies in vitro and in animal 

























Figure 1.1.3 Retinoids interfere with events leading to tumorigenesis at several levels: 
a) Block chemical carcinogenesis at the promotion step; b) Induce of 
cell differentiation and overcome a block in a differentiation pathway; c) 
Block cell cycle at G1 phase; d) Induce apoptosis; e) Induce premature 
cell death; f) Induce apoptosis alone or in combination with 
chemotherapy by activating of death receptors and/or their cognate 
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Table 1.1.2 Clinical effects of retinoids in cancer therapy* 
Compound 
(trade name) 















Pilot studies indicate efficacy 
in dedifferentiated thyroid 
cancer after standard 
treatment, has been combined 









Pilot studies with 14 patients; 
95% showed no gross 
histological changes and no 













Topical treatment, FDA 
approved; Tumor regression 
and antitumor activity in 
combination with IFNα2α 
 





Breast cancer  
 
Promising results in a Phase I 
trial in combination with 
tamoxifen; Phase II trial 
recommended. 
 






Phase I-II trials; Phase III 
trials; combination with 
IFNα2β/INFα2α not 
recommended; decreased 
quality of life 
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Table 1.1.2 Clinical effects of retinoids in cancer therapy (continued) 
Compound 
(trade name) 







Standard treatment; increased 
expression of RARβ mRNA 
 




Three-year prospective study 
in five patients with 
xeroderma pigmentosum; 
63% reduction of skin cancer; 
tumor frequency increased 
8.5-fold after drug was 
discontinued. 
 
Kraemer et al., 
1988 
  
Head and neck 
cancer 
 
Prevention of second primary 
tumors; Phase II trial, 
combination with INFα/α-
tocopherol is promising as 
adjuvant therapy for locally 
advanced squamous-cell 
carcinoma of the head and 
neck; Phase III trial initiated. 
 
Hong et al., 1990; 




Phase III trial with high-risk 
patients; high-dose pulse 
therapy with 13-cis RA after 
completion of intensive 












Pilot study with 30 patients 
shows some activity 
 





Pilot study with 16 patient 
showed modest antitumor 
effect 
 




Pilot study showed possible 
acitivity 
 
Park et al., 1998 
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Phase I trial with 23 patients 
showed moderate activity; 
combination with INFα 
 
 









Long-term reduction of skin 
cancer in renal transplant 









Effect in prevention of 
contralateral disease in pre-
menopausal women in 







Reduction of new occurrence 
 





Pediatric Phase I trial in 
combination with 








Bladder cancer  
 





Clifford et al., 
2001 
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1.2 Melanoma 
         The incidence of skin cancer in humans has been accelerating at an alarming rate 
for the past decade, and this has been attributed in large part to increased solar UV 
radiation exposure due to depletion of the ozone layer (Lee, 1989). Human skin cancer 
can be divided into two types: melanoma and non-melanoma skin cancer. Basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) are jointly referred to as non-
melanoma skin cancers (NMSCs). Both arise from keratinocytes, but they are clinically 
and histologically distinct. Epidemiologic studies have consistently associated NMSC 
with cumulative sun exposure (Henriksen et al., 1990). The prevalence of NMSC 
correlates inversely with the degree of skin pigmentation and geographic latitude (Boring 
et al., 1993). These tumors generally occur in older individuals and are the most 
frequently diagnosed malignancies in the United States, accounting for about 40% of all 
cancer diagnoses (Parker et a, 1997). Although mortality due to NMSC is much lower 
than that due to melanoma, local destruction can be quite extensive, accounting for 
significant morbidity. Typically, SCC is invasive and more than 10% will metastasize 
(Kwa et al., 1992; Moller et al., 1979). BCC can be locally invasive and destructive 
(Miller, 1991). While rarely fatal, BCC is associated with significant morbidity (Randle, 
1996). 
 
         Melanoma accounts for 1-3% of new cancer cases in the US. The American Cancer 
Society estimates that there will be 59,580 new cases of melanoma and 7,770 deaths from 
melanoma in 2005 (Rager et al., 2005). It is a disease that affects persons of all ages, with 
a median age at diagnosis in the mid-40s. Exposure to sunlight is an important risk factor 
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for the development of malignant melanoma. Intermittent exposure, especially early in 
life, seems to be more important than simple cumulative exposure (Lew et al., 1983).  It 
is speculated that increased recreational exposure to the sun has contributed to the rising 
incidence of melanoma. Early primary melanoma is highly curable, but once malignant 
melanomas invade subcutaneous tissues and spread to other organs, it is nearly always 
fatal. The overall survival rate has more than doubled from 40% in the 1960s to more 
than 80% today, but this increase is attributed to earlier diagnosis rather than to treatment 
advances (Andersen et al., 1995).  
 
       The neoplastic transformation of melanocytes gives rise to malignant melanoma. 
Melanocytes, cells of neural-crest origin, migrate to the skin and several other peripheral 
sites early during fetal development. They normally reside in the basal layer of the 
epidermis. They have dendritic processes that contact keratinocytes and they synthesize 
the pigment melanin, which is an important protective factor against the damaging effects 
of B-range ultraviolet light. Melanocyte-stimulating hormone supports the growth of 
melanocytes and causes increased production of melanin by the cells, while melatonin 
suppresses melanocyte function under conditions of decreased ambient light. 
Melanocytes respond to other paracrine growth factors as well, and malignant 
melanocytes produce growth factors themselves that may function in short autocrine 
loops to stimulate melanoma growth (Rodeck and Herlyn, 1991). 
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       Malignant melanoma has four major subtypes with unique clinical features: 
superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and 
acral lentiginous melanoma (Balch et al., 1993).  
 
           Superficial spreading melanoma constitutes approximately 70% of melanomas. 
It generally rises in a preexisting nevus. In early stage, superficial spreading melanoma is 
a flat lesion with mixtures of deeply pigmented areas and amelanotic foci. As the lesion 
grows, the surface may become irregular, and the perimeter may show indentation.  
 
             Nodular melanoma is the second most common pattern of growth (15 – 30 %). 
The lesion is typically blue-black and it generally begins in uninvolved skin on the trunk, 
head, and neck areas. Nodular melanomas lack the radial growth phase typical of other 
melanomas and therefore have sharply demarcated borders. They are more aggressive 
and usually develop more rapidly than do superficial spreading melanoma.  
 
             Lentigo malignant melanoma, the third subtype, constitutes 4% to 10% of all 
melanomas and is typically located on the faces of older white women. It is characterized 
by large, flat lesions and is always associated with sun-related changes in the dermis and 
epidermis.  
 
            Acral lentiginous melanoma, the fourth type of malignant melanoma, represents 
only 2% to 8% of melanomas in whites. However, in dark-skinned patients, such as 
blacks, Asians, and Hispanics, it accounts for 35% - 60% of melanomas. Acral 
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lentiginous melanomas occur on the palms or soles or beneath the nail beds. The 
characteristics of these four subtypes of malignant melanoma are summarized in Table 
1.2.1. 











Site Clinical features 








back in both 
sexes 
Raised border on 
palpation or 
inspection; pinks, 
whites, grays, and 






















Flat irregular border; 
predominantly dark 
brown to black with 
highly irregular 
border with areas of 
regression; brown-
tan macular lesion 
with variation in 
pigment pattern; 
may be amelanotic. 
 
Type with no radial growth phase 
Nodular 
melanoma 15 - 30% Months 
Mid to 
late 40s Any site 
Nodule arises in 
apparently normal 
skin or in a nevus; 
brown to brown-
black; may have 
bluish hues; may be 
amelanotic. 
* Modified from Bailin et al., 2002 
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          There are three less common types of malignant melanoma deserving to be 
mentioned due to their distinctive clinical presentations and poor prognoses.  
 
          Desmoplastic melanoma is a melanocyte-derived neoplasm of the skin involving 
the epidermis but with a predominantly dermal tumor focus. Survival rate of this kind 
melanoma is worse than for the common cutaneous melanoma, because dissemination 
occurs early.  
 
           Uveal melanoma, a rare and clinically peculiar type, arises from the melanocytes 
of the pigmented uvea. It is curable when detected at an early stage. Unfortunately, most 
of the time, uveal melanoma presents at a more advanced stage, has an extremely poor 
prognosis, and has a propensity to metastasize to the liver (Shields, 1993).  
 
            Mucosal melanoma arises in mouth, anus, external or internal genital tract, upper 
respiratory tract, or elsewhere in the gastrointestinal tract. It also tends to present as 
advanced local disease and has an aggressive natural history leading to death. Mucosal 
melanomas seem to be less responsive to therapy than are the standard cutaneous types 
(Cooper et al., 1982). 
 




Chapter 1. Introduction      
 25
        Surgical removal of metastatic deposits can play an important role in the 
management of disseminated melanoma. The goal of surgical excision is to render the 
patient free of disease and provide relief (Andersen et al., 1995). While radiotherapy 
plays a limited role in the management of metastatic melanoma, it is used mainly for 
palliation of central nervous system metastases or painful bone metastases and for control 
of pain and bleeding from recurrent cutaneous or lymph-node masses. As single-agent 
chemotherapy, only dacarbazine has been approved for a long time. Response rates are 
about 15-20%, and complete remission occurs in less than 5% (Andersen et al., 1995). 
Recently, temozolomide, a more active derivative of darcarbazine has been approved by 
FDA (Middleton et al., 2000). Nitrosoureas also have a significant but lower level 
antitumor activity in melanoma, with response rates around 15%. But, thus far, there is no 
effective chemotherapeutic treatment for advanced melanoma (Saida, 2001). Cisplatin 
and vinca-alkaloids have showed a low level of activity10-20% (Andersen et al., 1995). 
Multiagent chemotherapy has been studied broadly and studies of such regimens 
including dacarbazine and cisplatin have shown better response rates around 37%  
(Andersen et al., 1995). Interferon α showed some effect against metastatic melanoma in 
addition to a broad range of immunological effects (Parkinson et al., 1992). There have 
been multiple randomized trials assessing the use of interferon-α in high-risk melanoma 
patients. A variety of interferon-α dose levels and treatment schedules are investigated in 
these trials (Inman et al., 2003; Gogas et al., 2004) The results indicated that high-dose 
interferon-α2b improved relapse free survival and likely improved melanoma-specific 
survival as well. Intermediate or low-doses of interferon may have potential merits, but as 
of yet have not been shown to improve survival (Pawlik and Sondak, 2003). 
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1.3 Pharmaceutical Applications of Cyclodextrin 
        Cyclodextrins are cyclic oligosaccharides composed of 6-8 units of glucopyranose, 
linked by α-1,4 glycosidic bonds. They were first isolated from starch degradation 
products by Villiers in 1891 (Villiers, 1891). Twelve years later, Schardinger laid down 
the fundamentals of cyclodextrin chemistry (Schardinger, 1903). However, the output of 
cyclodextrins was quite small until 1970 and high production costs prevented their 
widespread application in pharmaceutics. Recent years, biotechnological advancement 
made possible dramatic improvements in cyclodextrin production, thereby making 
available sufficient cyclodextrins and cyclodextrin derivatives, which are suitable as 
pharmaceutical excipients. They are mainly used to improve the aqueous solubility, 
stability, and bioavailability of drugs by forming inclusion complexes with drugs. More 
and more pharmaceutical products are reaching the market place as cyclodextrin 
formulations and research studies investigating their applications are growing 
exponentially. Some of the approved and marketed cyclodextrin based pharmaceutical 
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Table 1.3.1 Commercial Pharmaceutical Products containing cyclodextrins* 
Drug Product Trade Name Formulation type Company Country 





PGE2/α-CD Prostarmon E Sublingual tablet Ono Japan 
OP-1206 /α-CD Opalmon Sublingual tablet Ono Japan 
Cefotiam hexetil 





































Ointment Ointment Fujinaga Japan 
Nitroglycerin/ β-
CD Nitropen Sublingual tablet Nippon Kayaku Japan 
Chlorideazepoxide/ 
β-CD Transillium Tablet Gador Agentina 
Thyaprofenic acid/ 




1297/β-CD Meiact Tablet Meiji Seika Japan 
Hydrocordisone 




CD Prepulsid Suppository Janssen-Cilag Begium 
Itraconazole/HP-β-




β-CD Vfend i.v. Pfizer 
United 
States 
*Modified from Stella and Roger, 1997  
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1.3.1 Chemical structure and physicochemical properties of cyclodextrins 
         Cyclodextrins (CD) are cyclic oligosaccharides obtained from the 
glucosyltransferase enzyme (CGT) degradation products of starch. The three major 
cyclodextrins are α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin, which are built up 
from six, seven, eight glucopyranose units, respectively.  
          The chemical structures of cyclodextrins show cylindrical shape with relatively 
hydrophobic central cavity and the hydrophilic hydroxyl groups on their outer surface. 
Owing to lack of free rotation about the bonds connecting glucopyranose units, the 
cyclodextrins are not perfectly cylindrical molecules but are, to some extent, truncated 
cone shaped. Based on this architecture, all the primary hydroxyl groups are located at 
the narrow side while all the secondary hydroxyl groups are located at the wider side. 
Figure 1.3.1 illustrates the chemical structure of three natural cyclodextrins and their 
approximate dimensions. Physicochemical properties of α-, β-, γ-cyclodextrins are given 
in Table 1.3.2. The hydroxyl groups locating on the edge of β-cyclodextrin ring are 
illustrated in Figure 1.3.2. 
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Figure 1.3.1 Chemical structures of nature cyclodextrins 
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Table 1.3.2 Characteristics of α-, β-, γ-cyclodextrins* 
 α β γ 
No. of 
glucopyranose units 6 7 8 
Empirical formula 
(anhydrous) C36H60O30 C42H70O35 C48H80O40 
Molecular weight 972.85 1134.99 1297.14 
Central cavity 
diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3 
Height of torus (Å) 7.9 7.9 7.9 
Approx. volume of 
cavity (Å3) 174 262 427 
Water solubility at 
25 °C (g/100ml) 14.5 1.85 23.2 
Crystal forms (from 
water) Hexagonal plates 
Monoclinic 
parallelograms Quadratic prisms 
αD, deg +150.5 +162.0 +177.4 
pKa (25 °C) 12.33 12.20 12.08 
 
*Modified from Conners, 1997 and Loftsson and Brewster, 1996 
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Figure 1.3.2 Hydroxyls located on the edge of β-cyclodextrin. Arrows indicate the 2-,   
3-, and 6- hydroxyls of a glucopyranose unit. (adapted from Uekama  et 
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          The parent CDs contain 18 (α-CD), 21 (β-CD) or 24 (γ-CD) hydroxyl groups, 
which can be modified chemically. The C6-OH groups are the most reactive, whereas the 
C3-OH groups the least reactive. However, the difference between their reactivity is not 
great; therefore the homogeneous pure derivatives are not produced on industrial scale. 
The ideal modified cyclodextrin should be safe, manufactured at a reasonable cost, and of 
a quality suitable for pharmaceutical application. Although hundreds of modified 
cyclodextrins have been prepared and shown to have research applications, only the 
derivatives containing the hydroxypropyl (HP), methyl (M), and sulfobutyl ether (SBE) 
substituents are ready for commercial application in pharmaceutical industry. Glucosyl 
and maltosyl cyclodextrins, which contain a mono-(G1-β-CD) or disaccharide (G2-β-CD) 
substituent, have also been reported and show promise as pharmaceutical excipients 
(Yamamoto et al., 1989). Because of the molecular dimensions (more suitable cavity 
diameter) and the price, the β-CD derivatives have attracted practical importance in 
pharmacy. Their chemical structures are listed in Table 1.3.3. Methylated substitution of 
β-CD dramatically improves the water solubility of the parent β-CD. The main reason for 
the solubility enhancement is that the introduction of the methyl groups disrupts the 
intramolecular hydrogen bonds between secondary OH groups in β-CD. At the same time, 
the methylated substitution transforms the crystalline β-CD into amorphous mixtures of 
isomeric derivatives Besides the very heterogeneous, noncrystallizable, randomly 
methylated β-CD (RM-β-CD), two well-defined methylated β-CDs have been studied for 
potential use in pharmaceutical industry: the heptakis (2,6-di-O-methyl)- and heptakis 
(2,3,6-tri-O-methyl)- β-CD (DM-β-CD and TM- β-CD).  
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          A 2-hydroxypropyl group will be connected to one or more hydoxyls of β-CD 
when reacting β-CD in alkaline solution with propylene oxide. The hydroxypropyl-β-CD 
(HPBCD) is an amorphous white powder. The HPBCD preparations are very soluble in 
water; no precipitation can be observed when their aqueous solutions are warmed. The 
drug solubilizing capacity of HPBCD, which depends on the substitution degree and 
patterns, and concentration, is in most cases lower than that of DMBCD. But HPBCD is 
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Table 1.3.3 Chemical structuresa of typical β-cyclodextrin derivativesb 
 
Cyclodextrin Abbreviation R 
Carboxymethyl-β-cyclodextrin CM-β-CD CH2COOH or H 
Carboxymethyl-ethyl- β-cyclodextrin CME-β-CD CH2COOH, CH2CH3 or H 
Diethyl- β-cyclodextrin DE-β-CD CH2CH3 or H 
Dimethyl- β-cyclodextrin DM-β-CD CH3 or H 
Trimethyl- β-cyclodextrin TM-β-CD CH3  
Random methyl- β-cyclodextrin RM-β-CD CH3 or H 
Glucosyl- β-cyclodextrin G1-β-CD Glucosyl or H 
Maltosyl- β-cyclodextrin G2-β-CD Maltosyl or H 
Hydroxyethyl- β-cyclodextrin HE-β-CD CH2CH2OH or H 
Hydroxypropyl- β-cyclodextrin HP-β-CD CH2CHOHCH3 or H 
Sulfobutylether- β-cyclodextrin SBE-β-CD (CH2)4SO3Na or H 
a Derivatives may have different degree of substitution at the 2, 3 and 6 positions. 
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1.3.2 Cyclodextrin inclusion complexes  
        The three-dimensional structure of CD provides a cavity (Figure 1.2.2) that is 
hydrophobic relative to an aqueous environment. When this cavity is filled with 
hydrophobic drug molecule, it is called an inclusion complex.  CDs are capable of 
forming inclusion complexes with many drug molecules by including a whole molecule, 
or part of it, into the cavity. The CD molecules are called the “host” molecule and the 
drug molecules that insert into the cavity are the “guest” molecules. No covalent bonds 
are broken or formed during this process. In aqueous solution, the complexes readily 
dissociate and free guest molecules are in equilibrium with the molecules in complex 
form (Figure 1.3.3). There is no simple explanation for the driving force for the complex 
formation. Although release of enthalpy-rich water molecules from the CD cavity is 
thought to be an important driving force for drug-CD complexation, other forces may 
also contribute to it (Loftsson and Brewster, 1996). These forces include van der Waals 
interactions (Nishijo and Nagai, 1991), hydrogen bonding (Tong et al., 1991), 
hydrophobic interaction, release of ring strain in the CD molecule, and changes in 















                                                                 




   
                                            
 
 
Figure 1.3.3 Equilibrium binding of drug and cyclodextrin to form 1:1 complex     
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1.3.2.1 Evaluating inclusion complexation 
          Phase solubility study is one of the most common methods of evaluating the ability 
of the CD to complex the drug (Higuchi and Conners, 1965). It involves adding excess 
amount of the drug to successively increasing concentrations of CD solutions. The 
suspensions are brought to solubility equilibrium by prolonged agitation at constant 
temperature. The solution phases are analyzed for total solute content. A phase diagram is 
constructed by plotting the molar concentration of dissolved drug versus the 
concentration of CD. Higuchi and Conners (1965) classified the phase solubility profiles 
into two types: Type A where soluble inclusion complexes are formed and Type B where 
complexes of limited solubility are formed (as shown in Figure 1.3.4). 
 
          In Type A profiles, the solubility of the drug increases as the concentration of CD 
increases. Soluble complexes are formed between the drug and CD, thereby increasing 
the total amount of the drug in solution. Depending on the nature of the complexes 
formed, the profile can be linear, AL, or curved in a positive, AP, or negative, AN, fashion. 
The complex formation with a 1:1 stoichiometry gives the AL type profile, whereas the 
higher order complex formation in which more than one CD molecules are involved in 
the complex gives AP type. The AN type is uncommon. It may be associated with an 
alteration in the nature of the solvent in the presence of high concentrations of CD or self-
association of CD at high concentration.  Type B profiles are observed when complexes 
of limited solubility are formed. In the case of BS type, the initial ascending portion of 
solubility change is followed by a plateau region and then a decrease in the solubility at 
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higher CD concentrations, accompanying a microcrystalline precipitation of the complex. 








Figure 1.3.4 Possible types of phase solubility profiles 
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           The stability constant and the stoichiometry of the complexes can be determined 
by quantitatively analyzing these profiles (Higuchi and Conners, 1965). If a 1:1 complex 
is formed, the stability constant K1:1 can be determined from the slope of the phase 
solubility curve, and the intrinsic solubility, S0, of the drug, using the following equation:     
 
                                                   
K1:1 =    Slope
S0 (1-Slope)  
 
 
            Additional methods (Hirayama and Uekama, 1987) are available to determine 
these stability or association constants including spectroscopy (UV, Fluorescence, NMR, 
ORD-CD) (Qi et al., 1994; Duran-Meras et al., 1994; Ndou et al., 1993), potentiometry 
(Valsami et al., 1992), microcalorimetry (Koenigbauer MJ, 1994) and freezing-point 
depression studies (Suzuki et al., 1988). Chromatographic methods include HPLC 
(Agnus et al., 1991) and TLC (Csabai et al., 1993) techniques. The stability constant 
obtained by different methods often correlates.  However, the pH conditions have been 
observed to exert a unique effect on one method and not the other. For example, 
Doxorubicin and γ-CD form a complex with a K1:1 of 617 and 718 M-1 as measured at pH 
10 by UV and circular dichroism (Bekers et al., 1990). This close correlation was not 
observed when the measurements were conducted at pH 7 where the binding constant 
was 235 M-1 as measured by UV but 977 M-1 as measured by circular dichroism (Husain 
et al., 1992). Under a given set of conditions, the drug has only one binding constant. 
Therefore, these differences may reflect how the ionization state of the drug affects the 
analytical measurements.  
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       In general, binding constants can be used as an indicator of differences in binding 
only if the methods or conditions for determining the constants are equivalent or 
unaffected by the conditions. Although determining values by phase solubility might be 
appropriate for formulation studies, it is probably not appropriate for the determination of 
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1.3.2.2 Factors affecting complexation 
          CD structure: Cyclodextrins are capable of forming inclusion complexes with 
drugs of a suitable molecular size. If only certain groups or side chains insert into the 
cavity, CD may form complex with molecules significantly larger than the cavity. The 
three different natural CDs, α, β, γ, have different internal cavity diameters, thus are 
capable of accommodating molecules of different sizes. 
 
           Derivatization of the hydroxyls on one or both faces of the natural CDs can impact 
the steric requirements for an acceptable guest molecule. The presence of bulky groups 
can sterically block the entrance to the CD cavity. However, some groups, depending on 
their number, flexibility, and position of substitution, may actually act to extend the 
cavity and provide for better complexation. Yoshida et al. (1989) have shown that 
introduction of the 3-hydroxypropyl substituent at a molar degree of substitution of 6 
results in higher stability constants than those observed with β-CD, apparently due to the 
extension of the hydrophobic cavity. 
 
         pH- Neutral vs. Ionic Drugs: Changing the ionization state of a drug may affect its 
binding to the CD. Generally, CDs bind the neutral form of a drug more effectively than 
the ionic form. Otero-Espinar et al. (1992) reported that the association constant for 
naproxen and β-CD was 1379 M-1 when the drug was neutral (pH = 1), but at pH 7 when 
the drug was completely ionized, the association constant was only 27 M-1. Van der 
Houwen et al. (1993) observed a similar effect in complexing mitocycin C by γ-CD. 
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When the pH changed from 1.8 to 4.8, the association constant increased from 48 to 249 
M-1. Under these conditions, the drug changed from cationic to neutral.  
 
         Temperature: Inclusion complexation is an equilibrium process where the strength 
of the association is affected by the temperature of the system. In most cases, the 
association constant decreases as the temperature increases. For example, the association 
constant for the neutral naproxen molecule and β-CD decreased from 1379 to 975 and 
778 M-1 as the temperature increased from 25 to 35 and 45 °C, respectively (Otero-
Espinar et al., 1992).  
        
          Water soluble polymers: It has been shown that, at low concentration, water-
soluble polymers enhance the complexing ability of CDs (Savolainen et al., 1998). In 
aqueous solutions, water soluble polymers increase the solubilizing effect of CDs on 
various hydrophobic drugs by increasing the binding constants of the drug-CD complex. 
For example, the solubilizing effect of 10% (w/v) HPBCD solution on a series of drugs 
and other compounds was increased from 12 to 129% when 0.25% (w/v) 
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1.3.2.3 Benefits of complexation 
           The aqueous solubility of hydrophobic drugs are dramatically improved by 
forming complex with CDs, and the drug-CD complex often exhibits better dissolution 
characteristics than other drug formulation. As a result of these two features, the oral 
bioavailability of the drug can be improved when solubility and the rate of the dissolution 
are limiting drug absorption. A review of the literature reveals over 200 citations and 
reviews that report the effects of complexation on dissolution and bioavailability of drugs 
(Uekama, 2004). Although these studies demonstrate the general application of 
complexation for improvements in dissolution rate and bioavailability, the use of 
complex may not be practical for some dosage forms because of the amount of CDs 
required. For example, β-CD has a molecular weight of 1135. Over 350 mg of CD is 
required for a 25 mg dose of a drug having a molecular weight of 400 with a mole ratio 
of 5:1 to improve solubility. This can limit the type and dose of drug that are suitable for 
forming complex with CDs.  
 
           The effect of cyclodextrins on the chemical stability of drugs in aqueous solution 
is another useful property of these excipients. The process of inclusion of drug into 
cyclodextrin can be regarded as molecular encapsulation, i.e., encapsulation of drug at the 
molecular level. The cyclodextrin molecule shields, at least partly, the drug molecule 
from a potentially corrosive environment and, in this way, reduce or even prevent drug 
hydrolysis, oxidation, steric rearrangement, isomerization, polymerization and even 
enzymatic decomposition. Doxorubicin, an anticancer drug, is unstable in aqueous 
solutions, undergoing acid catalyzed hydrolysis and photo-decomposition. Husain et al. 
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(1992) showed doxorubicin forms a stronger complex with γ-cyclodextrin than with β-
cyclodextrin and that, in general, γ-cyclodextrins are more effective than β-cyclodextrin 
to stabilize doxorubicin. Aspirin (acetylsalicylic acid), a phenolic acetate ester, is 
unstable in aqueous solution. Loftsson et al. (1993) demonstrated that the hydrolysis of 
this drug in aqueous solution was 4-6 times slower with the cyclodextrin complex than 
outside it. The authors found that the cyclodextrins did not influence the kinetic behavior 
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1.3.2.4 Preparation and characterization of inclusion complexes 
          Methods for preparing drug-cyclodextrin complexes have been reviewed (Hedges, 
1998; Veiga et al., 2001). In solution phase, the most common procedure is to stir or 
shake an aqueous solution of cyclodextrin with an excess amount of drug. The suspension 
is then filtered or centrifuged to obtain a clear drug-cyclodextrin complex solution. When 
the water is removed from the complex solution, solid formulations of the drug-
cyclodextrin complex can be formed. In the solid phase, a more or less amorphous 
inclusion complex is prepared by thoroughly co-grounding mechanical mixtures of 
crystalline cyclodextrins and crystalline or liquid drug substances in a vibration mill or a 
ball mill under normal humidity with or without heat treatment. In the so-called 
“kneading” method the cyclodextrin is intensively kneaded with a small amount of water 
to which the calculated amount of the drug is added directly without any solvent. Finally 
the water is removed from the paste-like product by drying in an air stream.  
           
          Various methods have been used to confirm the formation of cyclodextrin 
inclusion complexes. In solid phase, thermal analysis (e.g. DSC), X-ray analysis, infrared 
spectroscopy, rate of dissolution, vacuum sublimation and vacuum drying have been used 
(Aigner et al., 2005; Baboota and Agarwal, 2005). Cyclodextrin encapsulation of a 
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1.3.3 Cyclodextrins in various pharmaceutical formulations 
       The major purposes of using cyclodextrins in parenteral drug delivery are to deliver 
sparingly water soluble drugs rapidly and quantitatively for intravenous and 
intramuscular dosing, decrease irritation at the site of administration of parenterally 
administered drugs, and stabilize drugs unstable in an aqueous environment.  
 
       Upon administration, drugs appear to be rapidly and quantitatively released from the 
cyclodextrin inclusion complexes. Dissociation due to dilution seems to be the major 
release mechanism. Other factors such as competitive displacement of the drug from the 
complex, drug binding to plasma and tissue components may also contribute for the 
release of the more strongly bound drugs. The effect of CD on the pharmacokinetics of 
the drugs after intravenous administration was highlighted in many studies. Estes et al. 
(1990) evaluated a nonsurfactant formulation of alfaxalone containing cyclodextrin in 
rats and dogs, which was compared to a veterinary product containing the surfactant 
Cremophor-EL. No difference in anesthetic activity was seen between the two 
formulations in rats and dogs.  Stella et al. (1995) compared i.v. bolus pharmacokinetics 
in rats of methylprednisolone/cyclodextrin inclusion complex solution and a co-solvent 
solution of methylprednisolone (60% PEG 400, 12% ethanol, made up to 100% volume 
with water). There were no significant differences in any of the pharmacokinetic 
parameters between the two formulations.  Zou et al. (2002) showed that 
pharmacokinetic profiles were identical after intravenous administration of either 
HPBCD/flutamide inclusion complex or flutamide solution (dissolved in co-solvent). 
Based on these studies, a conclusion could be drawn that drugs are qualitatively and 
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quantitatively released from their inclusion complexes with little if any perturbation of 
the pharmacokinetics of the drug.  
 
         To date, only a limited number of studies have been performed to assess whether 
cyclodextrins modify the intrinsic irritancy of a drug after iv or im administration. It 
appears that irritancy from an agent is partially correlated to the agent’s ability to cause 
red blood cell hemolysis. Nagase et al. (2002) demonstrated that cyclodextrin protected 
red blood cell from hemolysis and morphological changes caused by the novel 
cytoprotective agent DY9760e. Stella et al. (1995) studied the tissue damage in rabbits of 
predisolone administered i.m. from an SBE-β-CD solution compared to a 
PEG400/alcohol/water mixture (4:1:5). SBE-β-CD was shown not to cause elevation of 
the intracellular marker, creatine kinase (CK), compared to an isotonic aqueous control 
solution while the co-solvent significantly raised CK levels, suggesting much greater 
tissue irritation from the co-solvent. McIntosh et al. (2004) also demonstrated that a 
formulation in a SBE-β-CD solution reduced the extent of hemolysis experienced after IV 
etomidate administration. 
 
        Applications of CDs in oral formulation include improvement of bioavailability 
through an increase in apparent rate and extent of drug dissolution, improvement of drug 
stability or release time during gastrointestinal (GI) transit through modification of drug 
release site and/or time profile, reduction of drug induced irritation, and objectionable 
taste masking. It is generally recognized that the gastrointestinal absorption of CDs is 
limited due to their bulky and hydrophilic nature. Thus, CDs are supposed to act only as 
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carrier system and help to transport the drug through an aqueous medium to lipophilic 
absorption surface in GIs. Only a free form of the drug is capable of penetrating 
lipophilic surface in GI and eventually entering the system circulation. Commercial 
formulations usually contain a large quantity of pharmaceutical excipients. These 
excipients and other endogenous substances existing in absorption site may compete 
with the drug for the cyclodextrin cavity. The displacement of the drug from the 
cyclodextrin cavity by these substances is responsible for acceleration of the drug 
absorption (Tokunaga et al., 1986). The overall process of drug absorption from the 
























Figure 1.3.5 Systemic absorption of drug from its cyclodextrin complex through 
biological membranes in the presence of the competing agent. 
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            The effect of increased drug dissolution rate and extent on bioavailability in the 
presence of cyclodextrins is most apparent in studies, which administer the drug 
cyclodextrin complex. Jarvinen et al. (1995) reported the use of HPBCD and (SBE)4M- 
β-CD to improve the bioavailability of cinnarizine in beagle dogs. The drug was orally 
administered as a suspension in phosphate buffer, solutions of the HPBCD or (SBE)4M- 
β-CD complex, and in a capsule as the solid (SBE)4M- β-CD. The results demonstrated 
that the absolute bioavailability of the CD complex solution or capsule was much higher 
than that of the suspension or neat capsule. Cyclodextrins may also alter oral absorption 
of the drugs through mucosal membrane permeation enhancement. Haeberlin et al. 
(1996) reported the cyclodextrin associated absorption enhancement of a modified 
calcitonin and the octapeptide octreotide in vitro using a Caco-2 cell monolayer and in 
situ using isolated rat jejunal sections. It was found that β-CD and HPBCD showed 
octreotide absorption enhancing properties in the in situ system. The parent 
cyclodextrins provided the greatest increases in peptide permeation in the Caco-2 cell 
monolayer model. 
 
             The use of cyclodextrins in dermal, ophthalmic, nasal, rectal, and pulmonary 
drug delivery has been extensively reviewed (Rajewski and Stella, 1996; Uekama, 2004; 
Challa et al., 2005). The major use of cyclodextrins is to improve either the local action 
of the drug through increased solubility or stability of the drug or the systemic delivery of 
the drug through a potential combination of these factors with a cyclodextrin-associated 
increase in membrane permeability.  









2.1 Investigation of effects of retinoids on murine melanoma cells (B16-   
      F10 cells) 
         Tumor metastasis is the major cause of cancer mortality. Although advances in 
surgery, radiotherapy and chemotherapy have significantly improved the treatment of 
primary tumor, the occurrence of metastasis still leads to poor prognosis and death in 
patients with malignancy.  A multi-step process leads to metastasis (Mareel et al., 1985). 
The interrelated events of the metastatic cascade include disruption of the basement 
membrane, cell detachment (separation), cell motility, invasion, penetration of the 
vascular system, circulating cancer cells, arrest (stasis), and extravasation and 
proliferation (McKinnell, 1998). Metastatic melanoma involves the escape of melanoma 
cells from the epidermis, growth and development of a blood supply, dissemination of 
melanoma cells to other organs, and their growth at these locations. Excess extracellular 
matrix (ECM) degradation is an essential step for cell migration (Stetler et al., 1993). 
Because matrix degradation is so central to the invasive/metastatic behavior of tumors, 
and because this metastatic ability is life-threatening, therapeutic strategies designed to 
inhibit invasion and keep a tumor localized are attractive.  
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          Among the several families of ECM-degrading enzymes, the most extensive are the 
matrix metalloproteinases (MMPs). MMPs belong to a large family of zinc-dependent 
neutral endopeptidases that together are capable of degrading a variety of ECMs. In 
addition, MMPs substantially contribute to other steps in the metastatic cascade, such as 
angiogenesis (Chambers and Matrisian, 1997). Overexpression of MMPs has been noted 
in a variety of malignant tumor types and their overexpression is also related with tumor 
aggressiveness and metastatic potential (Hidalgo and Eckhardt, 2001). In the invasion of 
tumor cells, different types of MMPs are involved. MMP-2 and MMP-9 found in 
malignant cancers like melanoma are postulated to play a critical role in tumor invasion 
and angiogenesis (Cockett et al., 1998). MMP-9 (gelatinase B) was first purified from 
neutral protease in neutrophils that could degrade gelatin (Sopata and Dancewicz, 1974). 
MMP-9 protein has been studied in many malignant tumor cells because of its inducible 
character (Gum et al., 1997). Several studies have revealed that the suppression of MMP-
9 reduces the invasive and metastatic ability of tumor cells (Himelstein et al., 1994; Shao 
et al., 1998; Jadhav et al., 2004). 
 
        Human malignant melanoma remains a devastating disease because of its increasing 
incidence and mortality and its high potential to dissemination. Despite rapid advances in 
understanding of melanoma, there are still many problems for the therapy of melanoma. 
Melanoma cells are highly resistant to chemotherapeutic agents, with therapeutic 
response rates below 30% in vivo and in vitro (Schadendorf et al., 1994). Five year 
survival is less than 10% and median survival is 6-8 months (Brown and Kirkwood, 
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2003). There is still no standard adjuvant treatment for patients with metastastatic 
melanoma. Thus, it is necessary to pursue new therapies and test their efficacy.  
 
         Retinoids as an anticancer agent have been studied in vivo and in vitro using various 
murine and human cancer cell lines including melanomas for more than twenty years. A 
number of retinoids have been evaluated as potential therapeutic agents in the prevention 
and treatment of human cancer (Lippmann et al., 1989). Oral administration of ATRA 
and synthetic retinoids has shown some promise against various kinds of cancer (Short et 
al., 2004; Estey et al., 2005; Serrano et al., 2005). The therapeutic effects of retinoids 
occur through several mechanisms such as inhibition of cell proliferation, induction of 
apoptosis, enhanced cell differentiation (Smith et al., 1992; Khuri et al., 1997), and, 
significantly suppression of tumor invasion (Hendrix et al., 1990; Helige et al., 1993). It 
was found that retinoids inhibited growth of many melanoma cell lines of various species 
(Siegrist et al., 1998; Ohashi et al., 2001; Emionite et al., 2003). Retinoids were also 
reported to suppress melanoma cell transformed phenotype and modulate their 
differentiation in vitro and formation of metastases in vivo (Hendrix et al., 1990; 
McGarvey et al., 1990; Wood et al., 1990; Lotan et al., 1992; Helige et al., 1993). The 
inhibitory effects of retinoids on metastasis may be partly due to retinoid-mediated 
repression of tumor cell motility (Hendrix et al., 1990; Helige et al., 1993) and 
suppression of MMP production (Borden and Heller, 1997; Schroen and Brinckerhoff, 
1997). However, not all retinoids inhibit melanoma cells; some have no influence and 
others even stimulate melanoma cell growth and invasion (Edward et al., 1989). 
Furthermore, some retinoids inhibit various functions in certain melanoma cells, while 
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these functions are not influenced in other melanoma cell lines using the same retinoids. 
Up to date, there is no systematic in vivo study comparing the effects of different 
retinoids on the metastases of melanoma. The purpose of this study is to evaluate the 
potential efficacy of 5 retinoids, all-trans retinoid acid (ATRA), 9-cis-retinoid acid (9-
cis-RA), 13-cis-retinoid acid (13-cis-RA), etretinate and acitretin, on the growth and 
invasion inhibition of murine melanoma cell line – B16F10 cell line.  
           
          Retinoids have shown a synergistic action in combination with other 
chemotherapeutic agents in numerous studies in vitro and in animal models (Ortiz et al., 
2002). Sacks et al. (1995) reported a synergistic interaction between ATRA treatment and 
cisplatin (CDDP) or 5-fluorouracil (5-FU) in a series of squamous cell lines. They 
inferred that mechanism of synergism would be based on drug perturbations in DNA 
synthesis coupled to an increased sensitivity induced by ATRA. Combinations of 13-cis-
RA and cisplatin or cisplatin and ifosfamide have proven promising in patients with head 
and neck cancer in phase I/II trials (Weisman et al., 1998; Recchia et al., 2001). 
Objective clinical responses with moderate toxicity have been observed in patients with 
advanced non-small cell lung cancer treated with 13-cis-RA and chemotherapy 
(carboplatin, vindesine and 5-FU) (Recchia et al., 1999). When combined with α-
tocopherol or cisplatin, 13-cis-RA was effective in two phase II clinical trials in patient 
with advanced squamous carcinomas of the head and neck or the skin (Shin et al., 2001; 
Shin et al., 2002). Thus, it may be meaningful to evaluate the effect of combining CDDP 
or 5-FU with retinoids on melanoma in vitro and in vivo. 
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         Numerous animal models have been developed for melanoma that can be used for 
testing of novel agents for treatment of melanoma (Bardeesy et al., 2000; Kusewitt and 
Ley, 1996), which include Sinclair swine, Camargue horses, Angora goats, Xiphorphorus 
fish, the marsupial opossum, guinea pig strains, Syrian hamster strains, transgenic mice, 
human melanoma xenografts and the B16 murine melanoma-C57/B16 model. The B16 
model has been the most extensively used for evaluation of melanoma metastases. Thus, 
this rapid, reproducible model with transplantable cells was used in the study for in vivo 
evaluation of retinoids effects on lung metastasis. 
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2.2 Development of cyclodextrin-based formulations of acitretin and  
      13-cis-RA 
       As reviewed in Chapter 1, all retinoids are almost insoluble in water. Thus, there is 
no commercial product available in the market and oral dosage of retinoids usually 
results in low and variable bioavailability. Retinoids are used broadly in dermatology. 
However, their topical use is limited due to several drawbacks: irritation, high instability 
in the presence of air, light and heat, and low aqueous solubility. It should be meaningful 
to investigate new formulation of retinoids. Their inclusion into cyclodextrins could 
possibly resolve these problems.  
 
        Several studies confirmed that β-CD was able to form inclusion complex with 
ATRA (Amdidouche et al., 1989; Montassier et al., 1997; Lin et al., 2000). Amdidouche 
et al. (1989) first reported that inclusion of ATRA into β-CD dramatically improved its 
aqueous solubility. Then, Montassier et al. (1997) demonstrated that ATRA can also 
form inclusion complex with DMBCD and HPBCD. These groups carried out these 
studies to develop new CD-based formulations of ATRA for topical delivery. Lin et al. 
(2000) reported that inclusion of ATRA in HPBCD can also improve the photostability of 
the drug and the preparation is suitable for parenteral administration. β-CD and its 
chemically modified CDs could have suitable cavity size to include other retinoids.  
           
           13-cis-RA, also known as isotretinoin, is a synthetic retinoid. The drug is the 13-
cis isomer of the naturally occurring ATRA. Modification of the terminal carboxyl group 
of retinoic acid to the cis configuration is associated with fewer adverse effects and 
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enhanced biological activity compared to the all-trans configuration (Veal et al., 2002). 
13-cis-RA is an extremely effective drug if given systemically in severe forms of acne. It 
was found effective as a chemopreventive agent of oral leukoplakia (Hong et al., 1986) 
and demonstrated to be able to prevent pre-malignant lesions and second primary tumors 
in the head and neck in clinical trials (Niles, 2000). It was also shown to reduce the 
severity of highly invasive urinary bladder carcinomas (Becci et al., 1978), decrease 
proliferation and induce differentiation in neuroblastoma cell lines, including some 
established forms of refractory tumors (Matthay et al., 1999). Under serum free 
conditions, 13-cis-RA has growth inhibitory effect on the small cell lung cancer cell lines 
(Avis et al., 1995). Evident from numerous studies conducted showed that 13-cis-RA and 
other vitamin A derivatives inhibit cell proliferation, induce cell differentiation and 
inhibit angiogenesis. All of these effects constitute potential anti-tumor activities (Bollag, 
1994). The therapeutic and preventive activity of 13-cis-RA as an anticancer agent is dose 
dependent (Bollag, 1994). However, during systemic administration, 13-cis-RA 
preferentially binds to serum albumin, limiting its availability for promotion of 
differentiation and inhibition of proliferation, thus impeding chemopreventive activity 
(Hong et al., 1986; Dahl et al., 2000). Currently, 13-cis-RA is given by oral systemic 
administration, but administration to the lung epithelium by inhalation is being 
investigated (Wang et al., 2000). 13-cis-RA is poorly absorbed during oral administration 
and has to be taken after food. Being lipophilic, the oral absorption of 13-cis-RA is 
improved by the presence of fats (Colburn et al., 1983). Improved aqueous solubility 
could also improve the oral absorption of 13-cis-RA. Since CDs could dramatically 
improve the solubility of ATRA and 13-cis-RA has a very similar chemical structure with 
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ATRA, it may be hypothesized that CD-based formulation of 13-cis-RA could also bear 
some advantages over the current formulations.  
 
        Acitretin, a second-generation of retinoids, has a chemical structure similar to 
ATRA (as shown in Figure 1.1.1). It is the main metabolite of etretinate. Etretinate 
represents one of the monoaromatic retinoid and has long been used in the systemic 
treatment of severe psoriasis and other dyskeratotic dermatoses (Christos, 2001). 
However, its clinical application is limited by its teratogenicity and other side effects 
(Christos, 2001). Etretinate is extremely slowly eliminated, with terminal half-life (t1/2) of 
~120 days. Several randomized clinical trials showed that acitretin is as effective as 
etretinate against psoriasis (Magis et al., 2000; Murray et al., 1991; Orfanos et al., 1997). 
Furthermore, acitretin has a more favorable pharmacokinetic profile, because it is 
eliminated more rapidly than etretinate (the elimination half-life of acitretin has been 
reported as 50-60 h) (Wiegand and Chou, 1998). Because acitretin and etretinate are both 
teratogenic, acitretin, with less potential of systemic accumulation, offers a clinical 
advantage. Unfortunately, as a member of retinoids, acitretin is insoluble in water and is 
quite lipophilic (Loftson et al., 1995). These physicochemical properties of acitretin 
limited its flux from topical formulation (Loftson et al., 1995). Thus acitretin can only be 
administered orally. However, the oral absorption of acitretin is irregular leading to 
highly variable bioavailability (McNamara et al., 1988). The poor oral bioavailability of 
acitretin might be attributed to limited aqueous solubility. Improved aqueous solubility of 
acitretin could lead to better oral absorption, as well as, enhanced therapeutic efficacy. 
Hence, it is necessary to develop new formulations of acitretin to solve these problems. 
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       Loftsson et al., (1995) investigated the effect of HPBCD, RMBCD, γ-CD and HP- γ-
CD on the solubility of acitretin. They found that these cyclodextrins could improve the 
solubility of acitretin, with RMBCD showed the most noticeable effect. Then, they 
focused on evaluating the effect of RMBCD on transdermal delivery of acitretin. The 
results of their study showed that it is possible to increase significantly the dermal and 
transdermal delivery of acitretin by cyclodextrin complexation. Based on their study, it is 
hypothesized that it is possible to develop cyclodextrin-based formulation of acitretin to 
improve its solubility, photostability and bioavailability.  
        
        Studies reported in this thesis were intended to develop cyclodextrin-based 
formulation of 13-cis-RA and acitretin, and to analyze their physicochemical 
characteristics. Phase solubility studies were performed to study the CD complexation 
behavior and calculate the stability constant of the inclusion complex formed. Molecular 
modeling was conducted as supplementary tool to understand the inclusion behavior of 
the CDs by predicting the inclusion modes and the stoichiometry of the complexes. These 
new formulations could be administered orally, intravenously or topically and could 
improve the efficacy of 13-cis-RA and acitretin, thus could be a good substitution for the 
current formulation. The biopharmaceutic properties of newly developed formulations of 
acitretin were studied and compared to the suspension of acitretin. 
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2.3 Pharmacokinetic studies of CD based formulation of acitretin in  
      Sprague-Dawley rats 
     Various pharmacokinetic studies of acitretin have been conducted in psoriatic patients 
under long-term therapy for months or for even longer duration (Meyer et al., 1993; 
Berbis et al., 1988). These studies have revealed that the elimination half-life of acitretin 
is around 50 h and its disposition is not associated with deep compartment storage. These 
are remarkable pharmacokinetic properties in contrast to etretinate, which is extremely 
slowly eliminated with a terminal half-life of about 120 days and has persistent tissue 
storage (Larsen et al., 1992; Orfanos et al., 1997). These properties would give acitretin 
an obvious clinical advantage. Clinically, acitretin is given by systemic administration. 
Commercial product of acitretin is Soriatane® (F. Hoffmann-La Roche Ltd.), which is 
available in capsule and administered orally. However, the oral absorption of acitretin is 
quite variable and increases with food (McNamara et al., 1988) due to its low aqueous 
solubility (Loftsson et al., 1995). 
       
          As reviewed in Chapter 1, CDs are useful to generate aqueous drug solution 
without the use of organic cosolvents, surfactant, or lipids, as formulation adjuncts, which 
increase oral bioavailability of poor water-soluble drugs, and as excipients used to 
generate safe intravenous dosage. Thus, it is anticipated that CD based formulation of 
acitretin would have more favorable biopharmaceutic properties than the parent drug. In 
the light of limited pharmacokinetic studies of intravenous acitretin to date, the 
pharmacokinetic and biopharmaceutic behavior of CD-based formulations of acitretin 
after single intravenous or oral administrations were investigated in this study. Biliary 
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excretion of acitretin and its β-glucuronide conjugate after intravenous administration of 
CD/acitretin complex solution was also investigated. The information obtained from this 





























3.1    Materials and methods 
3.1.1   Materials  
        All-trans-retinoid acid (ATRA) was purchased from Tokyo Chemical Industry 
Company, Ltd. (Tokyo, Japan). 13-cis-retinoid acid (13-cis-RA) was purchased from 
Sigma Chemical Co. (St. Louis, Mo, USA). 9-cis-retinoid acid (9-cis-RA), acitretin and 
etretinate were kindly provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). All 
retinoids were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 0.0 1M. 
They were diluted with culture medium to appropriate concentrations just before use. 
Cell culture medium DMEM, antibiotics and antimycotic solution, the dye reagent 
toluidine blue and DMSO (molecular biology grade) were all purchased from Sigma 
Chemical Co. (St. Louis, Mo, USA). Fetal bovine serum (FBS) was obtained from 
Hyclone (Logan Utah, USA). Matrigel (extracted from the Engelbreth-Holm-Swarm 
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3.1.2   Cell culture conditions 
         The murine melanoma cell line B16-F10 was ordered from the American Type 
Culture Collection (ATCC) (Manassas, Virginia, USA) and was tested to be pathogen 
free by ATCC. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heated-inactive fetal bovine serum and 1% antibiotic solution 
(penicilline/streptomycin) at 37°C in 5% CO2 humidified atmosphere. 
 
3.1.3   Animals 
        Experiments were performed on male C57BL/6J black mice, 6-8 weeks old, 
purchased from Laboratory Animals Center of National University of Singapore, 
Singapore. Mice were kept in plastic cages with sawdust bedding and given food and 
water ad libitum. The room in which mice were kept, in the Animal Holding Unit, 
National University of Singapore, Singapore, was environmentally controlled at a 
temperature of 23 ± 2 °C and with a 12:12 light-dark cycle. All animal experiments were 
carried out with the approval of Institutional Animal Care and Use Committee (IACUC), 
NUS, Singapore. 
 
3.1.4   Cell proliferation study 
           The inhibitory effect of retinoids was tested by incubating the B16-F10 cells with 
different retinoids. The cells were cultured in DMEM and were plated in 6-well plates in 
triplicate. After 12 h, and at every 48 h thereafter, the medium was replaced with fresh 
medium or medium containing retinoids (10-6 M).  The total viable cells in each well 
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were counted daily by trypan-blue dye exclusion method for 6 days after the medium 
were changed. All experiments were repeated in triplicate.  
 
3.1.5   Combination chemotherapy studies 
          The cytotoxicity of the respective chemotherapeutic agents (cisplatin [CDDP] or 5-
fluorouracil [5-FU]) combined with the retinoid was determined using a previously 
described fluorometric microculture cycotoxicity assay (FMCA) (Lasson et al., 1992). 
FMCA is based on the measurements of the fluorescence generated from the hydrolysis 
of fluorescein diacetate (FDA, Sigma) to fluorescein by cells with intact plasma 
membrane. Briefly, B16-F10 cells were grown for 6 days with or without retinoids (10-6 
M) and then plated onto 96-well microtiter plates (5000 cells per well) without retinoids. 
The plates were incubated at 37 °C overnight to allow the cells to adhere to the bottom. 
The medium of the plates was then changed to 200 µl medium containing CDDP or 5-FU 
or control medium. After 3 days incubation at 37 °C, the plates were washed with 
phosphate-buffered saline (PBS). The FDA stock solution (10 mg/ml) was diluted to 2 
µg/ml with PBS and 200 µl of this solution was then added to each of the control, 
experimental and blank wells. The plates were incubated for 30 min at 37 °C, and the 
fluorescence generated from each well was measured at an excitation wavelength of 485 
nm and an emission wavelength of 535 nm. It was shown (Lasson et al., 1992) that the 
fluorescence was proportional to the number of viable cells in the well. In each plate, 
wells with untreated cells were measured as controls and their fluorescence was defined 
as 100%. Cell survival is presented as survival index (SI), which was defined as the 
fluorescence in experimental wells expressed as a percentage of that in the control cells. 
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The 50% inhibitory concentration (IC50) of chemotherapeutic agents was defined as the 
concentration giving a SI 50%. Experiments were carried out in six replicates and 
repeated 3 times. The data were fit into Sigmoid Emax model with the software SPSS 
(version 11.0, SPSS, Chicago, Ill, USA). 
 
3.1.6     In vitro cell invasion assay 
        B16F10 cell invasion through reconstituted basement membrane (Matrigel) was 
assayed according to the methods as previously described (Albini et al., 1987) with some 
modifications. Before invasion assay, for each Transwell (pore size, 8 µm; Corning 
Incorporated, Corning, NY, USA), the upper surface of the microporous polycarbonate 
membrane that separated the upper and lower chambers was coated with Matrigel (10 
µg/well). B16-F10 cells were grown for 4 days with or without retinoids (1 µM). For the 
invasion assay, cells were detached by short exposure to trypsin; 100 µl of cells (106 
cells/ml) was suspended in DMEM supplemented with 0.1% bovine serum albumin 
(BSA), and seeded in the upper compartments of  transwell inserts. Conditioned medium 
(600 µl), obtained by incubating sub-confluent human fibroblast cells for 24 hr in serum-
free medium, was used as a source of chemo-attractants and placed in the lower 
compartments of the inserts. Cells were allowed for invading through the Matrigel for 6 h 
at 37 ºC. Cells remained on the upper surface of the inserts were wiped off by cotton 
swab. Cells which crossed the Matrigel barrier and migrated to the lower side of the 
inserts were fixed in 70% ethanol, stained by dipping the Transwell into solution of 
toluidine blue (1% v/v) for 1 min. The Transwell was then blotted dry on a piece of tissue. 
10 random unit fields per insert were counted by an inverted microscope (Leica, 
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Germany; 400× magnification). Only invasive cells were detectable on the lower surface 
of the inserts. Three different experiments in four replicates were performed.  
 
3.1.7     Western Blot Analysis 
          Control (untreated), ATRA treated (treated with 1 µm ATRA for 4 days), and 13-
cis-RA treated (treated with 1 µm 13-cis-RA for 4 days) B16-F10 cells were collected by 
scraping. The cells were extracted in lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM Nacl, 
1 mM EDTA, 1% v/v Triton X-100, 0.5% v/v NP-40) at 4 ºC. Protein of the resultant 
extract was estimated against bovine serum albumin by the Bradford method (Bradford, 
1976). Each lane was loaded with 50 µg protein separated on 8% SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and electro-transferred to a nitrocellulose membrane 
(Bio-Rad Laboratories, Hercules, CA, USA). The membrane was blocked with 10% w/v 
milk in TBS-T (Tris buffered saline with Tween-20; 50 mM Tris, 150 mM NaCl, 0.05% 
v/v Tween-20), incubated with anti-MMP9 polyclonal antibody (Chemicon, Temecula, 
CA, USA) for 1 h at room temperature, washed thrice in TBS-T, incubated with 
peroxidase-conjugated swine anti-rabbit immunoglobulins P 0399 (Dako, Glostrup, 
Denmark) for 1 h and washed thrice with TBS-T. Bands were visualized with 
chemiluminescence reagents (PerkinElmer, Boston, MA, USA). 
    
3.1.8    Experimental lung metastasis assay 
        To prepare B16F10 cells for inoculation, cells in logarithmic growth phase were 
harvested by exposure to trypsin. Cell viability in single cell suspensions was determined 
by trypan blue exclusion. A total of 105 B16F10 cells (> 90% viability) in 100 µl of PBS 
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were injected into the lateral tail vein of 6-8 week-old male syngeneic C57BL/6J mice. 
The mice were divided into 4 groups. The control group received saline of comparable 
volume to the drug solution and the treated groups received ATRA, 9-cis-RA and 13-cis-
RA (20 mg/kg), respectively over 10 continuous days. The day of inoculation was 
considered as day zero. After 14 days, mice were sacrificed; lungs were removed and 
fixed in 10% formaldehyde. Metastatic foci (black spot) at lung surfaces were counted 
under dissection microscope (MZ FL III; Leica Co., Inc., Tokyo, Japan). 
 
3.1.9   Effects of retinoids and cisplatin combination on tumor development in  
           C57BL/6J mice injected with B16F10 melanoma cells 
       On day 0, B16F10 melanoma cells were harvested from the cultures. 1×106 cells in 
20 µl PBS were injected subcutaneously (s.c.) into the footpad of the right hind limb of 
each mice. Mice were divided into 5 groups. Mice in control group were injected i.p. 
daily of saline of comparable volume to the drug solution for 10 days continuously. Mice 
in group 2 received cisplatin (10 mg/kg, i.p., on days 7 and 14). Mice in group 3 were i.p. 
administered of 13-cis-RA (20 mg/kg) daily for 10 days. Mice in group 4 received ATRA 
(20 mg/kg, i.p.) daily for10 days and received the same dose of cisplatin as mice in group 
2. Mice in group 5 received the 13-cis-RA (20 mg/kg, i.p.) daily for 10 days and received 
the same dose of cisplatin as mice in group 2. Mice in each group were weighted, the 
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3.1.10     Statistical Analysis 
       Differences among samples from in vitro tests and differences in lung metastasis and 
tumor size from in vivo experiments were analyzed for significance by one-way ANOVA. 
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3.2   Results 
3.2.1    Cell proliferation study 
      To test the inhibitory effect of different retinoids, cells were cultured in medium 
containing different retinoids for 6 days. Cell viability was more than 90% after treatment. 
The growth curves of cells treated with different retinoids were shown in Figure 3.2.1. 
Various inhibitory effects were observed depending on the type of retinoids. When 
treated at 1 µM, all retinoids significantly suppressed the proliferation of B16-F10 cells. 
However, the inhibitory effect of ATRA on the proliferation of cells was not different 
from the effect of 9-cis-RA and 13-cis-RA, while acitretin and etretinate showed less 
inhibitory effect compared to these drugs. Significant growth inhibition was found in 
cells treated with all retinoids, ranging from 24% (acitretin treatment) to 45% (ATRA 
treatment) after 6 days (Figure 3.2.2). The inhibition effects of these drugs could not be 
due to toxicity, as cell viability was more than 90%. In contrast to proliferation, no 
significant changes in cell morphology or pigmentation were observed for cells treatment 
with all retinoids (data not shown).  
 
3.2.2   Combination chemotherapy studies 
      B16-F10 cells were treated with 1 µM retinoid for 6 days and then examined for 
sensitivity to CDDP and 5-FU using FDA assay. The dose-dependent curves of CDDP 
and 5-FU in combination with different retinoids are shown in Figure 3.2.3. 
 
       Treatment of B16-F10 cells with different concentrations of CDDP (0.5-16 µg/ml) 
for 72 hr led to a marked dose-dependent cytotoxicity as determined in the FMCA. The 
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cells pretreated with retinoids showed different sensitivities to CDDP. The IC50 values of 
CDDP in cell with or without pretreatment of retinoids are shown in Table 3.2.1. 
Comparison of CDDP sensitivities with and without addition of retinoids shows that 
CDDP is more cytotoxic when combined with ATRA, 9-cis-RA or 13-cis-RA by at least 
1.50 fold, as seen by comparison of the IC50s of treatment with drugs alone and combined 
treatment (see Table 3.2.1). However, combined treatment of CDDP and etretinate or 
acitretin did not decrease the IC50 value of CDDP compared to the treatment of CDDP 
alone.  
         In contrast to CDDP, the cells pretreated with retinoids did not show significantly 
different sensitivity to 5-FU. The IC50 values of 5-FU in cell with or without pretreatment 












































Figure 3.2.1  Growth curves of B16-F10 cells in culture medium with or without 








































   Figure 3.2.2 Cell proliferation after 6 days of treatment with different retinoids.  
                        Each value was the mean obtained from at least 3 experiments. Each 
experiment had 3 replicates. Error bars represent S.D.  
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Figure 3.2.3 The cytotoxic effects of CDDP (a) and 5-FU (b) in combination with 
different retinoids on B16-F10 cells. With or without pretreatment of 
retinoid, the cells were treated with the indicated concentrations of 
CDDP or 5-FU for 3 days and then analyzed by the FMCA assay. The 
results are presented as means ± SD from 3 experiments. In each 













Table 3.2.1  Comparison of IC50 from exposure to CDDP alone or combined with 
different retinoids.  
 
 
Pretreatment IC50  value (µg/ml) aPotentiation 
Control 5.59 ± 1.20  bN.A. 
ATRA 2.52  ± 0.35* 2.33 
9-cis-RA 3.07  ± 0.42* 1.91 
13-cis-RA 3.93  ± 0.38* 1.50 
Etretinate 3.97  ± 0.53 1.41 
Acitretin 4.02  ± 0.75 1.39 
 
 
a   Potentiation was expressed as the ratio of the IC50 values of control and pretreated cells. 
The IC50 values given in the table represent the average of at least three independent 
experiments.  
b   Not available 





















Table 3.2.2  Comparison of IC50 from exposure to 5-FU alone or combined with 
different retinoids.  
 
 
Pretreatment IC50  value (µg/ml) aPotentiation 
Control 0.46 ± 0.14             bN.A. 
ATRA 0.26 ± 0.03* 1.79 
9-cis-RA 0.41 ± 0.07 1.12 
13-cis-RA 0.40 ± 0.13 1.15 
Etretinate 0.34 ± 0.06 1.35 
Acitretin 0.37 ± 0.18 1.24 
 
 
a   Potentiation was expressed as the ratio of the IC50 values of control and pretreated cells.   
The IC50 values given in the table represent the average of at least three independent 
experiments.  
b   Not available 
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3.2.3    Effects of retinoids on the invasion of B16-F10 cells 
        The inhibition of retinoids on melanoma invasion was investigated through the 
Transwell assay. The invasive potential of B16-F10 cells was determined on the basis of 
the cell’s ability to invade a Matrigel containing the major components of the basement 
membrane. Representative micrographs of Transwell filters are shown in Figure 3.2.5. 
Data are expressed as cell number/field ± standard deviation. For inhibition studies, non-
confluent cell cultures were incubated with different retinoids (1 µM; 96 hour-
pretreatment) under standard culture conditions. Except acitretin, all other retinoids 
induced significant decrease in Matrigel invasion of B16F10 cells (Figure 3.2.4). The 
inhibition of Matrigel invasion was respectively 43% for ATRA, 33% for 9-cis-RA, 40% 


































Figure 3.2.4 Effects of retinoids on the invasive ability of B16F10 cells in the in vitro 
Matrigel assay. Data were expressed as means ± SD of triplicate 
experiments.  
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 a        b 
 
 c         d 
 
 e         f 
Figure 3.2.5  Lower surfaces of an invasion membrane when B16-F10 was assayed 
for invasion a) without treatment; b) pretreated with ATRA; c) 
pretreated with 9-cis-RA; d) pretreated with 13-cis-RA; e) pretreated 
with etretinate; f) pretreated with acitretin. 
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3.2.4   Western blot analysis of MMP-9 
        On treatment of B16-F10 cells with ATRA and 13-cis-RA (1 µM for 4 days), MMP-
9 expression was reduced (Figure 3.2.6 lane 2 and 3) when compared with control B16-






          1             2     3 
 
 
Figure3.2.6 Western blot analysis on cell extracts. Lane 1: control cells; Lane 2: cells 
treated with ATRA (1 µM for 4 days); Lane 3: cells treated with 13-cis-
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3.2.5     Effects of retinoids on experimental lung metastasis in mice 
          The ability of retinoids to inhibit experimental lung metastasis after intravenous 
injection of B16-F10 cells in mice was investigated (Figure 3.2.7). All mice received 
either saline (in control group) or retinoids continuously for 10 days from the time of 
inoculation of B16-F10 cells. Administration of saline, 13-cis-RA and 9-cis-RA did not 
show any adverse effect on the growth of mice during the study. There were no 
significant differences in body weight gained among the groups throughout the study. 
However, administration of ATRA resulted in a drop of body weight as shown in Figure 
3.2.8.  
 
        The incidence and the numbers of metastatic lung tumors are indicated in Table 
3.2.3.  In control mice, 12.1 ± 4.9 colonies of metastasis foci were observed per lung at 
14 days after inoculation with B16-F10 cells. All the tested retinoids significantly 
reduced the overall number of gross lung metastasis and mean number of metastases per 
lung (Table 3.2.3). The relative decrease in the mean number of metastases in the ATRA 
treated mice was greater than that in the 13-cis-RA or 9-cis-RA treated mice, perhaps 
reflecting the more potent inhibitory effect of ATRA. The incidence rates of lung 
metastasis in the control group and the group treatment with 13-cis-RA or 9-cis-RA were 
all 100%. However, the frequency of lung metastasis in the group treatment with ATRA 
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   Figure 3.2.7 Representative photographs of mouse lung treated with or without 
retinoids a) control; b) treated with ATRA; c) treated with 9-cis-RA; 
d) treated with 13-cis-RA. Arrow indicates the metastasis foci. 
 
 
















































Incidence of lung 
metastasis 
No of metastasic lung 
tumors/mouse 
1 None 10 100% (10/10) 12.1 ± 4.9
2 ATRA, 20 mg/kg 10 90% (10/9) 3.7 ± 1.8a
3 13-cis-RA, 20 mg/kg 10 100% (10/10) 4.6 ± 2.8a
4 9-cis-RA, 20 mg/kg 6 100% (6/6) 8.3 ± 1.9b
 
a Significantly different from group 1 by Student’s t-test or Welch’s t test (p < 0.001) 
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3.2.6    Effects of retinoids and cisplatin combination on tumor development in mice  
            injected with B16F10 melanoma cells 
       ATRA (20 mg/kg), 13-cis-RA (20 mg/kg), and cisplatin (10 mg/kg), either alone or 
in combination, were given to the mice. The combination of cisplatin and ATRA resulted 
in death of all mice in the group, while the combination of cisplatin and 13-cis-RA 
resulted in only1 death of 6 rats. The survival curve was demonstrated in Figure 3.2.9.  
         
        The antitumor effect of the combination treatments of 13-cis-RA and cisplatin was 
higher than that of the corresponding single drug treatments (Table 3.2.4). When 13-cis-
RA was used alone, it did not show any antitumor effect compared to the control group. 
However, the number of pulmonary metastases was significantly decreased by the 
treatment of 13-cis-RA alone, and 13-cis-RA combined with cisplatin. Cisplatin alone did 
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Table 3.2.4 Effects of 13-cis-RA, cisplatin, either alone or in combination, on  
                    melanoma in C57BL/6J mice 
 
 
Treatment No of mice Tumor size (mm3) Metastatic incidence (%) 
No. of gross 
metastasis 
Control 6 1349 ± 712 4/6 (67) 13
13-cis-RA 6 1406 ± 635 1/6 (17) 1
Cisplatin 4 970 ± 431 2/4 (50) 5
Cisplatin + 13-cis-






































Figure 3.2.9 Survival curve of mice after treatment with retinoids and cisplatin, 
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3.3   Discussion 
       Retinoids exhibit a host of interesting effects on the growth and differentiation of 
normal, preneoplastic and neoplastic cells in vitro and in vivo and thus have gained 
attention in cancer prevention and treatment (Lippmann et al., 1989). Inhibitory effects 
have been reported in a broad spectrum of different epithelial and mesenchymal tumor 
cell types (Halter et al., 1988; Le-Ruppert et al., 1992) and also in mouse and human 
melanoma cells as reviewed by Lotan (1991). Mechanistically, inhibition has been 
attributed to cytostasis rather than cytotoxiciy since viability is maintained and growth 
arrest is reversible (Jeten, 1984). In good agreement with these earlier reports, significant 
inhibitory effect of a panel of 5 different retinoids (ATRA, 9-cis-RA, 13-cis-RA, 
etretinate and acitretin) was observed in mouse melanoma cell line: B16-F10 cells. The 
viability of treated cells was more than 90%. ATRA, 9-cis-RA, 13-cis-RA showed 
stronger inhibitory effects than did etretinate and acitretin. The effects of the various 
retinoids on melanogenesis were not absolute conclusive, but seemed to be more cell-line 
specific rather than retinoid specific. Only very few reports have described the 
differential effect of one retinoid on multiple melanoma cell lines (Hoal et al., 1982). 
Thus, these retinoids may also have antiproliferative effects on human melanoma cell line.  
         
          Several investigators reported that retinoids inhibited the invasion of tumor cells. 
Hendrix et al., (1990) and Wood et al., (1990) noted that retinoic acid inhibited the 
invasiveness of melanoma cells by the down-regulation of gelatinases, tPA, and a 
motility factor receptor, and up-regulation of laminin receptor. Jacob et al., (1998) 
reported that ATRA inhibited proliferation and chemotaxis in all tested human melanoma 
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cell lines, but invasion was specifically inhibited in the cell lines derived from metastases. 
In this study, only ATRA, 9-cis-RA, 13-cis-RA were found to inhibit the invasion of 
B16-F10 cells to Matrigel, while etretinate or acitretin showed little effect on it. Studies 
of tumor cell invasion into basement membrane have shown that DNA synthesis and cell 
proliferation are not required, whereas protein synthesis and proteolysis play important 
roles (Thorgeuirsson et al., 1984). These observations suggest that different intrinsic 
factors in tumor cells mediate the effects of retinoids on proliferation and invasion. It 
may be the reason that etretinate and acitretin showed significant anti-proliferative effects 
on B16-F10 cells, but showed little anti-invasive effects. 
 
           A number of previous studies have provided evidence that inhibition of tumor cell 
invasion by retinoids involves decreased production and secretion of collagenolytic 
metalloproteinases (Nakahana et al., 1989; Hendrix et al., 1990; Seftor et al., 1993). 
Interestingly, MMP-9 expression levels are especially high in lung carcinoma and 
melanoma cells (Salo et al., 1983). In B16-F10 murine melanoma cells, invasive potential 
has been related to the activity and expression of MMP-9 because it can degrade type IV 
collagen in the reconstituted basement membrane (Ho et al., 2002). Therefore, expression 
and retinoids-mediated regulation of MMP-9 were investigated. The data revealed that 
MMP-9 protein was indeed suppressed by the treatment with retinoids. It is not clear 
whether retinoids are able to directly inhibit the activity of the active form of MMP-9 or 
the activation/conversion of the latent form to the active form of MMP-9. Thus, the 
detailed inhibitory mechanism is not yet determined, but the result indicated that the anti-
invasive effect of retinoids is associated with inhibition of the enzymatic degradative 
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processes of tumor invasion. In order to evaluate whether the reduction of the lytic 
content of MMP-9 is due to a decrease in the amount of corresponding MMP-9 mRNA, 
the efficacy of MMP-9 gene transcription should be further detected by RT-PCR analysis. 
 
         The present study provides the first experimental evidence that ATRA, 9-cis-RA, 
and13-cis-RA suppressed experimental metastasis of B16-F10 melanoma cells in mice, 
as revealed by the small number of metastatic foci found in treated mice compared with 
that in untreated mice. In this study, metastatic potential was evaluated after direct 
injection of B16-F10 cells into the bloodstream via the tail vein. This model eliminates 
intravasation but is able to measure the ability of malignant cell to extravasate into the 
lungs. It was found that administration of retinoids decreased the number of metastatic 
tumors in the lungs. This suggests that retinoids affect extravasation of malignant cells.  It 
should be noted that only ATRA induced substantial weight loss in tumor-bearing mice 
(Figure 3.2.8), although ATRA treatment was most effective in inhibiting tumor 
metastasis (Table 3.2.3). This may suggest 13-cis-RA, with good inhibitory ability and 
moderate toxicity would be the more likely candidate for use in future clinical trials.  
 
          It was reported that retinoid treatment could produce growth inhibition but allow 
continuing DNA synthesis (Sacks et al., 1995), which provided a rationale for examining 
combination therapy with standard cytotoxics. Using B16-F10 cells, this approach was 
tested for combination with CDDP and 5-FU. An increased effectiveness was observed 
for combination of retinoids with CDDP, as revealed by a decrease in the IC50 value of 
CDDP. However, the combination of retinoids with 5-FU did not improve the efficacy of 
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5-FU. This suggests that the mechanism for synergism is complex and not just related to 
rates or levels of DNA synthesis itself. CDDP and 5-FU are cytotoxic through different 
mechanisms but both require DNA synthesis.   
 
         Animal experiments to determine whether combination of ATRA or 13-cis-RA and 
cisplatin has a suppressive effect on the growth and metastatic state of B16-F10 
melanoma cells in vivo were also performed. Antimetastatic activity was investigated by 
counting lung metastatic nodules as reported previously (Jani et al., 1993; Kang et al., 
2000; Feleszko et al., 2002), because B16-F10 melanoma cells preferentially induce lung 
metastasis (Jani et al., 1993; Gude et al., 2001; Malafa et al., 2002). All the mice died 
when they were treated with cisplatin and ATRA indicating that the combination of 
cisplatin and ATRA was too toxic at the administrated dose. Treatment with a 
combination of cisplatin and 13-cis-RA resulted in a significant reduction in primary 
tumor size and the numbers of lung metastatic nodules, while treatment of cisplatin alone 
only inhibited the primary tumor growth and 13-cis-RA treatment alone primarily 
suppressed metastasis of melanoma cells to the lung.  It was also obvious that the 
addition of 13-cis-RA to cisplatin resulted in greater suppression of primary tumor size 
than that in the case of treatment with cisplatin alone. These results suggest that 13-cis-
RA not only exhibits antimetastatic effect, but also potentiates the antitumor activity of 
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3.4    Conclusion 
       ATRA, 9-cis-RA, 13-cis-RA, etretinate and acitretin showed antiproliferative activity 
in B16-F10 cells in vitro. However, only ATRA, 9-cis-RA, 13-cis-RA inhibited cell 
invasion into the Matrigel. Their effect may be related to the suppressed expression of 
MMP-9 protein. ATRA, 9-cis-RA, 13-cis-RA showed antimetastatic effects on 
experimental lung metastasis model. Although ATRA was more potent than 9-cis-RA 
and 13-cis-RA, it was also more toxic. Combination of 13-cis-RA and CDDP could 
suppress the primary tumor growth and lung metastasis of melanoma cells with moderate 
toxicity. Thus, 13-cis-RA could be a likely candidate for the single or combination 
treatment of malignant melanoma in future clinical trials.  
       Most of the retinoids are almost water insoluble, which would affect its oral 
absorption. It will warrant developing new formulations of these drugs with improved 
biopharmaceutical properties to maximize their efficacy. Findings of the proposed studies 
are presented in the next chapter.  
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        Acitretin was supplied by F. Hoffmann-La Roche Ltd. (CH4002 Basel, Switzerland).  
13-cis-retinoic acid (13-cis-RA) was supplied by Ludwigshafen Co. (Germany). All-
trans-retinoic acid (ATRA) (internal standard) was purchased from Tokyo Chemical 
Industry Co., Ltd. (Tokyo, Japan). α-cyclodextrin (α-CD) was obtained from TCI Co., 
Ltd. (Tokyo, Japan). 2-hydroxypropyl-β-cyclodextrin (HPBCD) (degree of substitution = 
0.6) and randomly substituted methyl-β-cyclodextrin (RMBCD) (degree of substitution = 
1.8) were obtained from Roquette Ltd. (Lestrem, France) and Wacker-Chemie (Munich, 
Germany), respectively. All solvents used were of HPLC grade. Milli-Q water was used 
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4.2    Equipment 
       A Shimadzu (Japan) HPLC system that consisted of a LC-10Ai pump, SPD-10Ai 
UV-Vis detector, SIL-10Ai auto injector and SCL-10AVP system controller was used. 
Separation of acitretin and 13-cis-RA were performed by using a reverse-phase column 
(ODS Hypersil, 5 µm, 250 × 4 mm, Hewlett Packard, Germany) and detection was made 
at 340 nm. The mobile phase consisted of acetonitrile-methanol-2% ammonium acetate 
(55:25:20 v/v) mixture and the flow rate was 1.5 ml/min. ATRA was used as an internal 
standard. The calibration curve of acitretin or 13-cis-RA was linear (r2 > 0.99) over the 
range of 0.5-30 µg/ml. The in-between run coefficients of variation were less than 5% at 
all concentration levels. 
 
         Fourier transformed infrared spectrometer FT/IR-430 (Jasco Co., Japan), 
differential scanning calorimeter DSC2010 (TA Instruments Inc., USA), scanning 
electron microscope SEM XL30 FEG (Phillips, France) and D8 advanced X-ray 
diffractometer (Bruker AXS) were employed to characterize the physicochemical 
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4.3 Methods 
4.3.1 Special precautions 
          To avoid isomerization of acitretin and 13-cis-RA, all laboratory procedures 
involving the manipulation of acitretin were executed in a dimly lit environment. 
 
4.3.2 Phase-solubility study 
          Acitretin/cyclodextrin inclusion complexes in different buffer solutions (from pH 
7.4 to 9.0) were prepared by the method previously reported (Lin et al., 2000): an excess 
of acitretin (10 mg/ml) was added to cyclodextrin solutions of different concentrations (0, 
0.01, 0.02, 0.03, 0.05, 0.10, 0.15, 0.20, 0.30 M) and the suspension was sonicated for 1 h 
and then was shaken on a horizontal rotary shaker at a speed of 400 r.p.m. for 7 days; 
finally the suspension was filtered through a 0.45 µm membrane filter (Whatman Ltd.) to 
obtain a clear solution. All samples were prepared in triplicate. The concentration of 
acitretin in inclusion complex solutions was determined by HPLC assay.  
 
         Stability constants for inclusion complexes formation between acitretin and 
HPBCD or RMBCD were determined from the phase-solubility data (Higuchi and 
Cornners, 1965; Tinwalla et al., 1993; Okimoto et al., 1996). Because small changes in 
the final pH can lead to non-linear phase solubility plots, the binding constants of the 
ionized and non-ionized drug with the cyclodextrins were then estimated by analyzing the 
phase-solubility data using non-linear least squares regression as suggested by Tinwalla 
and coworkers. (SPSS 11.0, SPSS Inc. Chicago. IL) (Tinwalla et al., 1993; Okimoto et al., 
1996). 
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         13-cis-RA/cyclodextrin inclusion complexes in the respective phosphate buffer 
solutions (pH = 5.9, 7.4, 8.1) were prepared by the same method as for preparing 
acitretin/cyclodextrin inclusion complexes: an excess of 13-cis-RA (10 mg/ml) was 
added to cyclodextrin solutions of different concentrations (HPBCD: 0.01,0.02,0.03, 0.05, 
0.10, 0.15, 0.20, 0.30 M; α-CD: 0.01, 0.02, 0.03, 0.04, 0.05, 0.08, 0.10, 0.12 M) and the 
suspension was then shaken for 7 days. The resultant suspension was filtered through a 
0.45 µm membrane filter. The concentration of 13-cis-RA in inclusion complex solution 
was also determined by HPLC assay. 
 
4.3.3 Photostability study 
        The photostability of acitretin was assessed in the phosphate buffer solutions (pH = 
9) in which the cyclodextrin types and concentrations were manipulated. The 
photostability of 13-cis-RA was evaluated in the buffer solution (pH = 8.1) with different 
concentration of HPBCD (0.05, 0.10, 0.20 and 0.30 M) as well as in methanol. The initial 
drug solution was adjusted to 3 × 10-4 M in all tested solutions.  These solutions were 
kept at a distance of 30 cm away from a light source (six fluorescent tubes of 6 W each) 
in an incubator with temperature set at 37 ˚C. The solutions were sampled at the specified 
time intervals (0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0 h) and the quantities of retinoid were 
calculated. The results were expressed as percentages of the remaining retinoid. Each test 
was carried out in triplicate. 
 
         In all studies, reactions were performed under pseudofirst-order conditions. The 
observed degradation rate constant (kobs) was determined by linear regression analysis of 
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the natural logarithm of the percentages of the remaining acitretin as a function of time 
(SPSS 11.0, SPSS Inc. Chicago. IL). Degradation constants for retinoid included in the 
cyclodextrin cavity (kc) were determined using Lineweaver-Burk analysis (Brewster et al., 
1992). The following equation was used in this procedure: 
 
                              k0/ (k0-kobs) = k0/ {Kc (k0-kc) [CD]} + k0/ (k0-kc) 
 
where k0 is the first-order degradation rate of retinoid in the absence of cyclodextrin. kobs 
represents the degradation rate of retinoid in solutions containing cyclodextrin and [CD] 
is the cyclodextrin concentration of the solution. kc can be calculated from the slope of k0/ 
(k0-kobs) vs 1/ [CD].  
 
4.3.4 Preparation of the solid drug/CD complexes  
         The solid inclusion complexes were prepared by lyophilizing aqueous solutions of 
the complexes, according to a previous method (Erden and Celebi, 1988).  The required 
stoichiometric amount of acitretin/13-cis-RA was added to the aqueous solution of 
HPBCD/RMBCD. The mixtures were shaken at room temperature (25°C) for 2 days, and 
then filtered to remove the excess drug. The resulting solution was frozen at -80˚C and 
then subjected to lyophilization in a freeze-dryer to obtain the powders. Physical mixtures 
of acitretin/CD were prepared as follows: acitretin and CDs were separately pulverized in 
ceramic mortars. The calculated amounts of both compounds were weighed, mixed 
together and vortexed for 30 s and then mixed again with a spatula. 
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         The prepared inclusion complexes and the physical mixtures together with pure 
drug and CDs were then subjected to a series of physicochemical analyses. 
 
4.3.5 Infrared spectroscopy (IR) 
        The samples were ground and mixed thoroughly with potassium bromide (2:98 w/w). 
The discs obtained were used to obtain the IR spectra from 4000 cm-1 to 400 cm-1. 
 
4.3.6 Differential scanning calorimetry (DSC) 
          DSC measurements were performed on 2 mg samples in sealed aluminum pans. An 
empty aluminum pan was used as a reference. The scanning rate was 10°C min-1, from 
20°C to 240°C. 
 
4.3.7 Scanning electron microscopy (SEM) 
         SEM was carried out on samples adhered to double-sided adhesive tape on brass 
stubs. The samples were made electrically conductive in a vacuum by coating with gold. 
 
4.3.8 X-ray diffractometry (XRD) 
         X-ray analysis was carried out using an X-ray generator equipped with cobalt (Co) 
as anode material, operated at a voltage of 30 KV. The samples were analyzed in the 2θ 
angle range of 10-80° and process parameters were set as: Scan step size of 0.1° (2 θ), 
scan step time of 2.5 s and time of acquisition 0.5 h.  
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4.3.9 Molecular modeling 
         Molecular modeling was carried out to further elaborate the complexation modes. 
Dimethyl-β-cyclodextrin (DMBCD) was adopted as a substitution for RMBCD (degree 
of substitution = 1.8) to facilitate the determination of the stable structure of the 
acitretin/RMBCD complex. Because HPBCD with a degree of substitution of 0.6 was 
used for the experimental study, four 2-hydroxypropyl groups were added on the primary 
hydroxyl groups of β-cyclodextrin as shown by Mura et al. (1995). The structures of 
acitretin, 13-cis-RA, α-CD, DMBCD and HPBCD were individually minimized by 
MMFF94s force field using software, SYBYL ver.6.6 (Tripos). After thorough 
minimization, docking experiments were carried out on all molecules using the “DOCK” 
module in SYBYL. This allowed the drug molecule to move within the energy field of 
cyclodextrin and vice versa in order to find the preferable binding geometries. The drug 
molecule, in its favorable conformation, was introduced into the cyclodextrin cavity and 
the steric interaction energy was computed. The most likely conformation of the complex 
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4.4 Results and Discussion 
4.4.1 Phase solubility study 
         The pKa value and intrinsic solubility of acitreitn were calculated from the 
solubility of acitretin (at pH 7.4, 8 and 9) in the absence of cyclodextrin using linear least 
squares regression analysis (SPSS 11.0, SPSS Inc. Chicago. IL) (Okimoto et al., 1996). 
The solubility of acid drug under different pH values can be related to its dissociation 
constant (Ka) and intrinsic solubility (S0) as shown in equation: 
 
S = S0 (1 + Ka / [H+]) 
 
        After linear least squares regression of total solubility (S) as a function of 1/ [H+], 
the intrinsic solubility (S0) and the dissociation constants (pKa) of acitretin were 
determined to be 7.62 × 10-7 M and 5.10, respectively. These values were used in the 
subsequent binding constant determination. 
 
          The phase-solubility profiles of acitretin in the presence of HPBCD and RMBCD 
are shown in Figures 4.4.1 and 4.4.2, respectively. Several qualitative observations can be 
made from these figures. The apparent solubility of acitretin increased with increasing 
cyclodextrin concentrations and pH values.  The solubility of acitretin in the presence of 
RMBCD increased more than that in the presence of HPBCD at all pH values. In 0.3 M 
RMBCD (pH = 9.0), the aqueous solubility of acitretin reached 2.74 mg/ml, similar to the 
value reported previously (Loftsson et al., 1995). Slight deviations (AP or AN) from 
linearity were observed in some of the phase-solubility diagrams, depending on the pH 
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value (Figures 4.1.1 and 4.1.2). Despite this, all plots were not significantly deviated 
from linearity (p > 0.1 in all cases) suggesting the inclusion stoichimetry of acitretin with 
cyclodextrin was mainly 1:1. The slight deviation from linearity could be due to small 
changes in the final pH values (Okimoto et al., 1996). Because of this observation, 
analysis of phase-solubility data was performed by non-linear regression analysis as 
suggested by Tinwalla et al. (1993). 
 
         A mathematical model for 1:1 interaction between an acid agent and cyclodextrin 
was previously reported by Okimoto et al. (1996), as depicted in the following scheme: 
 
AH + CD 
A- + CD + H+
AH-CD






        The model takes into account of the ionization of the acid agent and the fact that 
both the anion and neutral species form 1:1 complexes with cyclodextrin with different 
constants. 
 
        In this scheme, Kc is the binding constant for the complex formed between neutral 
acid (AH) with the cyclodextrin; Kc’ is the binding constant for the complex of anion (A-) 
with the cyclodextrin. Ka is the dissociation constant of the acid and Ka’ is the effective 
dissociation constant of the acid in the complexed form. 
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        According to the scheme, the total solubility of the agent (S) and the total 
concentration of the cyclodextrin ([CD]T) are given by the following equations: 
 
S = [AH] + [A-] + [AH-CD] + [A-CD]                              (1) 
[CD]T = [CD] + [AH-CD] + [A-CD]                                 (2) 

























          By combining Eqs 1 to 7, the total solubility of the drug as given by Eq. 1, as a 
function of [H+] and [CD]T, can be related back to its intrinsic solubility (S0), dissociation 
constant (Ka), and its ability to form inclusion complexes with cyclodextrin, defined by 
Kc and Kc’.  
 
          Phase-solubility data of acitretin was fitted into this model by non-linear least 
squares regression analysis to determine the values of Kc and Kc’. The results are 
presented in Table 3.4.1. The upper plots in Figures 4.4.1 and 4.4.2 display the 
experimental solubility versus the model calculated solubility. The good linearity and 
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randomness of the data around the slope of unity support the suitability of this model for 
describing the solubility of acitretin over the range of experimental conditions. The 
binding of acitretin in its neutral and charged form, as indicated by Kc, Kc’ values, was 
always superior for RMBCD compared to HPBCD. This may be due to the extended 
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Figure 4.4.1 Upper plots: Observed versus calculated solubility of acitretin in  
solutions varying in pH, RMBCD concentration. Lower plot: Phase-
solubility profiles of acitretin in the presence of RMBCD varying pH 






Chapter 4. Development of cyclodextrin based formulations of retinoids 
 104


















































Figure 4.4.2 Upper plots: Observed versus calculated solubility of acitretin in 
solutions varying in pH, HPBCD concentration. Lower plot: phase-
solubility profiles of acitretin in the presence of HPBCD varying pH 
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Table 4.4.1  Binding Constants (M-1) and Standard Errors (SE) for the Inclusion 




Estimate (M-1) SE Estimate (M-1) SE 
HPBCD 4.33 × 103 4.94 × 102 8.75 × 101 8.90 × 100 
RMBCD 2.33 × 104 1.25 × 103 1.57 × 102 2.79 × 101 
 
 
        Inspection of the results presented in Table 4.4.1 clearly shows the higher affinity 
for cyclodextrin of acitretin in its neutral form compared to its ionized form. However, 
the highest solubility was achieved in the highest pH value solutions where the 
predominant species in solution was the ionized acitretin. As suggested by Tinwalla et al. 
(1993), this phenomenon occurred because the concentration of ionized acitretin, which 
acts as the driving force for complex formation, far exceeds that of the neutral species at 
higher pH values. 
 
       The solubility profiles of 13-cis-RA/HPBCD, 13-cis-RA/α-CD complex are shown in 
Figures 4.4.3 and 4.4.4, respectively. From the figures, it is evident that the apparent 
solubility of 13-cis-RA in the presence of HPBCD increased more than that in the 
presence of α-CD at all pH values. This may be because the cavity size of HPBCD is 
more suitable to include 13-cis-RA molecule than that of α-CD. As HPBCD proved to be 
a more effective solubilizing agent for the drug, the inclusion constants of 13-cis-
RA/HPBCD complex were calculated and subjected to further physicochemical tests.  




































Figure 4.4.3 Phase solubility profiles of 13-cis-RA/HPBCD inclusion complex. (The   













































Figure 4.4.4 Phase solubility profiles of 13-cis-RA/α-CD inclusion complex. (The  
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         Inclusion of 13-cis-RA into HPBCD dramatically improved its aqueous solubility 
and was further enhanced by pH adjustment. The complexation of 13-cis-RA with 
HPBCD at lower pH value (pH = 5.9) displayed a typical Ap-type solubility curve 
(Higuchi and Connors, 1965) with two linear segments, indicating the formation of 1:1 
and 1:2 inclusion complexes. At low concentration of HPBCD, a 1:1 inclusion complex 
is formed. However at high concentrations of cyclodextrin, formation of a 1:2 inclusion 
complex is favored: one drug molecule is complexed with 2 molecules of HPBCD. At 
higher pH values, (pH = 7.4 and pH = 8.1), the phase solubility curve displayed a typical 
AL-type indicating the formation of 1:1 inclusion complex even at high concentration of 
HPBCD. This may be due to the effect of ionization of the 13-cis-RA molecule at higher 
pH. The inclusion constants of 13-cis-RA/HPBCD were calculated using the following 
equations and the values are listed in Table 4.4.2:  
 
K1:1 = Slope1/So·(1-Slope1)    
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Table 4.4.2 Inclusion constants of 13-cis-RA/HPBCD complexes 
pH K1: 1  (M-1) K 1: 2(M-1) 
5.9 50.8 508.0 
7.4 13563. - 




      As can be observed from Table 4.4.2, the stability constant of 13-cis-RA/HPBCD 
complex at pH 7.4 is larger than that at 8.1. This is because at pH 7.4, there is a higher 
proportion of unionized drug compared to pH 8.1 and unionized drug molecule usually 
forms a more stable complex than its ionic counterpart (Loftsson and Brewster, 1996). 
This is consistent with the finding (Szejtli and Osa, 1996) that stated the stability constant 
of the CD complex is much larger for the un-ionized than for the ionized form of the drug. 
The phase solubility studies measured the total amount of 13-cis-RA (ionized and 
unionized) complexed with HPBCD, indicating that at pH 8.1, there were more 13-cis-
RA (ionized or neutral form) complexed with CD than at pH 7.4 (t-test, p < 0.005). The 
data derived from the phase solubility study and the calculation of inclusion constant 
indicated that at pH 8.1, most of the inclusion complex formed was that of the ionized 13-
cis-RA molecule and HPBCD, whereas at pH 7.4, most of the inclusion complex formed 
was that of the neutral 13-cis-RA molecule and HPBCD.  
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4.4.2 Photostability study 
        An investigation on the photostability of acitretin seemed to be interesting since the 
molecule has five conjugated “C=C” in its structure (Figure 4.4.5) and it is known that 
conjugated polyenes like those in the retinoids are very sensitive to light (Liu and Asato, 
1984). In this study, the photostability of acitretin in aqueous solutions of various 
compositions were examined. In all cases, photodegradation of acitretin followed the first 
order kinetics and the rate constant data indicated that both cyclodextrins had a 
















Figure 4.4.5 Lineweaver-Burk analysis for degradation of acitretin in the presence   
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        To further evaluate the effect of various cyclodextrin on acitretin stability at constant 
temperature (37 °C) and pH (pH = 9), Lineweaver-Burk analysis was completed for the 
degradation of acitretin in the presence of HPBCD and RMBCD (Table 4.4.3 and Figure 
4.4.6). The results showed that the degradation constants of acitretin included in 
cyclodextrin cavity (kc = 0.251 h-1 for HPBCD and kc= 0.238 h-1 for RMBCD, 
respectively) are nearly 2 times lower than the degradation rate of acitretin in the absence 
of cyclodextrin (k0 = 0.457 h-1). Such photo-protective effect of cyclodextrins has 
similarly been observed in the previous study with ATRA (Lin et al., 2000). 
 
          Acitretin undergoes degradation by isomerization at the alkyl side chain when 
exposed to light (Liu and Asato, 1984). As shown in the molecular model of 
DMBCD/acitretin complex, the side chain of acitretin was included in the cyclic 










































Figure4.4.6 Effect of HPBCD and RMBCD on the rate of degradation of acitretin at    
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Table 4.4.3 Influence of HPBCD and RMBCD on the Degradation of Acitretin 
                   at pH 9 and 37 °C 
 
Cyclodextrin k0 (h -1) kc (h -1) r2 
HPBCD 0.457 0.251 0.99 
RMBCD 0.457 0.238 0.99 
          
         k0, rate constant for degradation of free acitretin; kc, rate constant for degradation of  
acitretin within the complex; r, correlation coefficient for Lineweaver-Burk linear 





          
 
       The photostability of 13-cis-RA was examined in aqueous solutions of varying 
HPBCD concentrations. A control was carried out using a solution of 13-cis-RA in 
methanol, in the absence of CD. The data produced indicated that HPBCD delayed the 
photo degradation of 13-cis-RA, in effect making the drug more stable under light. The 
degradation of the drug in all cases studied, followed first order kinetics.  
 
       Lineweaver-Burk analysis was also carried out for the degradation 13-cis-RA in the 
presence of HPBCD to further evaluate the effect of different CD concentrations on the 
stability of the drug at a constant temperature of 37ºC and pH 8.1 (Figure 4.4.7). The 
degradation constant of 13-cis-RA within CD cavity (kc = 0.06 h-1) is more than 7 times 
lower than the degradation of free drug (k0 = 0.43 h-1). This may be also due to the side 
chain of 13-cis-RA being included into the oligosaccharide ring of CD.  








Figure 4.4.7 Effect of HPBCD on the rate of degradation of 13-cis-RA at pH 8.1,    
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4.4.3 Physicochemical characterizations 
4.4.3.1 IR spectra 
        Acitretin was characterized by bands around 1700-1500 cm-1 corresponding to C=O 
of the drug stretching vibration and 1300-1100 cm-1. The IR spectra of CDs showed 
intense bands at 3600-3200 cm-1, corresponding to absorption by hydrogen-bonded -OH 
groups. The bands which appeared at 3000-2800 cm-1, were assigned to stretching 
vibrations of the bonds in –CH and –CH2 groups. In the physical mixtures, the spectra 
were the superposition of that of the pure compounds with attenuation of the acitretin 
peaks. However, the spectra of inclusion complexes showed rightward shift (from 3405 
to 3387 cm-1 for HPBCD/acitretin complex and from 3431 to 3420 cm-1 for 
RMBCD/acitretin complex, respectively) of the band corresponding to hydrogen-bonded 
OH group. This suggested that some of the existing bonds formed between the OH 
groups on the narrow side of cyclodextrin molecules might be disturbed after the 
formation of inclusion complexes.  
 
        In physical mixtures of 13-cis-RA and HPBCD, the spectra obtained were akin to 
the superimposition of the individual spectra of 13-cis-RA and HPBCD. However, the 
spectra of 13-cis-RA/HPBCD complex showed a shift from 3406 cm-1 to 3423 cm-1 of the 
band corresponding to hydrogen-bonded OH group. The intense bands that were 
observed in the physical mixture at 1700-1500 cm-1 (corresponding to C=O of the drug 
stretching vibration) were also significantly reduced in the spectra of complex. This is 
consistent with the phenomenon observed for acitreitn/CD complex.  
 







Figure 4.4.8 IR spectra of (a) physical mixture of RMBCD and acitretin; (b) 
physical mixture of HPBCD and acitretin; (c) acitretin/RMBCD 












Figure 4.4.9 IR spectra of (a) 13-cis-RA (b) HPBCD (c) physical mixture of 13-cis-
RA    and HPBCD (d) 13-cis-RA: HPBCD complex 
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3.4.3.2 Differential scanning calorimetry (DSC) 
        Evidence for the interactions between acitretin and cyclodextrins could be obtained 
from thermal analysis (Figure 4.4.10). When guest molecules are included in CD cavities 
or in the crystal lattice, their melting, boiling and sublimation points shift to different 
temperatures or disappear (Sztatisz et al., 1981). The thermograms of HPBCD and 
RMBCD presented broad endothermic effects, with a maximum at around 50°C. The 
DSC trace of acitretin exhibited a sharp endothermic peak at 227.8°C, corresponding to 
the melting point of the drug. The drug endothermic peak and the CDs dehydration peaks 
were all present in the thermograms of the mixtures of acitretin with the respective 
HPBCD and RMBCD, as if these thermograms were only the superposition of their own 
components. Thus, the absence of interaction between acitretin and CDs in these systems 
could be suggested. The complete disappearance of acitretin endothermic peak was 
observed for both acitretin/HPBCD and acitretin/RMBCD inclusion complexes, 
indicating the strong interaction between acitretin and HPBCD/RMBCD. 
          The thermogram of 13-cis-RA has sharper peak around 170ºC which is 
corresponding to the melting point of the drug (Figure 4.4.11). For the physical mixture 
of 13-cis-RA and HPBCD, the thermogram is similar to the superimposition of the 
thermogram of individual 13-cis-RA and HPBCD, thus indicating that there may be a 
lack of interaction between them in physical mixture. However there is a complete 
disappearance of the 13-cis-RA peak in the thermogram of the 13-cis-RA/HPBCD 
complex, which suggests there is strong interaction between them in the inclusion 
complex. 
 









                          
Figure 4.4.10 DSC thermograms of (a) HPBCD; (b) physical mixture of 
acitretin/HPBCD; (c) acitretin/ HPBCD complex; (d) RMBCD; 
(e) physical mixture of acitretin/RMBCD; (f) acitretin/RMBCD 
complex; (g) acitretin 





Figure 4.4.11 DSC thermograms of 13-cis-RA, HPBCD, physical mixture of  
                       13-cis-RA and HPBCD, and 13-cis-RA/HPBCD complex  
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4.4.3.3 Scanning electron microscopy (SEM) 
         Scanning electron microscopy (Figure 4.4.12) showed that the inclusion of acitretin 
into cyclodextrins led to the formation of new materials. Acitretin appeared as well 
defined lamellae. HPBCD powder consisted of spherical particles, whereas RMBCD 
powder was in globular forms. The presence of unmodified particles of HPBCD/RMBCD 
was evident in the physical mixture of HPBCD/RMBCD and acitretin, although the 
cyclodextrin powders were covered by drug lamellae. For the freeze-dried products of the 
cyclodextrins/acitretin inclusion complexes, the original morphology of the raw materials 
disappeared and it was impossible to differentiate the separate components. This 
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a     b 
c     d 
e    f 
g 
Figure 3.4.12 Scanning electron microscopy photographs of (a) physical mixture 
                        of HPBCD/acitretin; (b) physical mixture of RMBCD/acitretin; (c) 
HPBCD /acitretin inclusion complex; (d) RMBCD /acitretin inclusion 
complex; (e) HPBCD; (f) RMBCD; (g) Acitretin 
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3.4.3.4 X-ray diffractometry (XRD) 
        The XRD patterns of acitretin/HPBCD and acitretin/RMBCD systems are shown in 
Figure 4.4.13. The X-ray powder diffractogram of pure acitretin exhibited a series of 
intense peaks, which is indicative of its crystalline character. However patterns of 
HPBCD and RMBCD are all amorphous. Patterns of physical mixtures are practically 
constituted by the superposition of the spectra of the single components, indicating no 
formation of new form. The complexes, irrespective the mother cyclodextrin, presented 
diffraction patterns completely diffuse, which revealed their amorphousness. The results 
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Figure 4.4.13 X-ray diffraction (a) HPBCD, physical mixture of acitretin/ HPBCD,  
acitretin/ HPBCD complex, and acitretin (from bottom to top); (b) 
RMBCD, physical mixture of acitretin/ RMBCD, acitretin/ RMBCD 
complex, and acitrtin (from bottom to top); (c)13-cis-RA, HPBCD, 
13-cis-RA:HP-β-CD complex, and physical mixture of 13-cis-RA 
and HPBCD (from top to bottom). 
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4.4.4 Molecular modeling 
        As RMBCD is a mixture of different structures, DMBCD was used in this study as a 
substitution of RMBCD. Two inclusion modes were adopted to perform the docking. The 
alkyl chain was introduced into the DMBCD cavity in mode 1, while in mode 2, the 
benzene ring was inserted into the cavity and allowed to dock freely. After many trials 
the resultant preferred structure of the complex showed mode 1 as the choice of inclusion 
and the corresponding steric and total energy values were found to be -26.55 and -28.11 
kcal/mol, respectively. The hypothetical structure of the complex was showed in Figure 
4.4.14. The alkyl chain of acitretin stretched across of the DMBCD cavity. The benzene 
ring of the acitretin molecule orientated at the rim of the wider side of cavity.  Similar 
study with acitretin/HPBCD complex was also carried out. The orientation of acitretin in 
the HPBCD was found to be the same as in the DMBCD cavity, while the steric and total 
energy values were -20.67 and -21.73 kcal/mol, respectively. This indicates that the 
interaction between acitretin and DMBCD might be stronger than that between acitretin 
and HPBCD. This finding was consistent with the result of the phase-solubility study.    
 
        Two inclusion modes were adopted to perform the docking of 13-cis-RA. The alkyl 
chain was introduced to the CD cavity in mode 1, while the cyclohexene ring was 
inserted into the cavity and allowed to dock freely in mode 2. The preferred mode of 
docking of 13-cis-RA was found to be mode 1 after numerous trials. The alkyl chain of 
13-cis-RA enclosed by the CD cavity, with the cyclohexene ring oriented at the rim of the 
wider side of the CD cavity. For the 13-cis-RA/α-CD complex, the computed total energy 
is -21.9 kcal/mol and the steric energy is -18.15 kcal/mol. For the 13-cis-RA/HPBCD 
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complex, the total energy is -31.38 kcal/mol and the steric energy is -27.29 kcal/mol. This 
result indicated that the interaction between 13-cis-RA and HPBCD might be stronger 
than that between 13-cis-RA and α-CD, which was consistent with the results of the 
phase solubility study.  
 
        The present study illustrated that computational molecular modeling could be 
applied to predict the binding and protecting ability of various CDs. This suggests that in 
the development of new chemically modified CDs or formulations of CD complexes, the 
CD molecules and their complexes can be assessed computationally for its feasibility 
even before the actual synthesis and experiments are carried out. This will expedite the 
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Figure 4.4.14 Hypothetical structure of acitretin-DMBCD complex. (a) Side-view      
                        without surface (b) Side-view with surface (c) Top-view without 
surface (d) Top-view with surface. 
 
 














Figure 4.4.15 Modeling of docking of 13-cis-RA in α-CD (a) without, (b) with 
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4.5 Conclusion 
        Acitretin and 13-cis-RA formed inclusion complexes with different cyclodextrins 
with different binding constants. The energy scores obtained from DOCK (SYBYL) 
showed a positive correlation with the binding constants. Both of these cyclodextrins 
showed stabilizing effects on acitretin and 13-cis-RA by decreasing the photodegradation 
rate constant of the drug.  
 
        Retinoids were used widely for topical or systemic treatment of skin disorders and 
also for therapy and/or chemoprevention of skin cancer and other neoplasia. However, 
this family of drugs is almost insoluble in water and is light sensitive. These drawbacks 
made the formulation a problem. From the findings of this study, cyclodextrin could be a 
promising excipient for the formulations of retinoids. The biopharmaceutical properties 
of the acitretin/CD complexes were then studied and the results were presented in the 
next chapter. 
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5.1 Special Precautions 
        To prevent the degradation of acitretin, all laboratory procedures involving the 
manipulation of acitretin were executed in a dimly lit environment.  
 
5.2 Materials 
        Acitretin was donated by F. Hoffmann-La Roche Ltd. (CH4002 Basel, Switzerland).    
2-hydroxypropyl-β-cyclodextrin (HPBCD) (degree of substitution = 0.6) and randomly 
substituted methyl-β-cyclodextrin (RMBCD) (degree of substitution = 1.8) were gifts 
from Roquette Ltd. (Lestrem, France) and Wacker-Chemie (Munich, Germany), 
respectively. β-glucuronidase (Type B-3: from bovine liver, 4000 U/mg), ammonium 
acetate and sodium chloride were purchased from Sigma Chemical Co. (St. Louis, MO). 
All solvents used were of HPLC grade. Milli-Q water was used to prepare buffer 
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5.3 Analytical Procedure 
5.3.1 Measurement of Acitretin in Plasma 
        Acitretin concentration in plasma was determined using a previously reported 
reversed phase high-performance liquid chromatography (HPLC) method with some 
modifications (Jakobsen et al., 1987). Briefly, 300 µL acetonitrile was added to each 100-
µL of plasma sample to precipitate proteins. The mixture was vortex-mixed for 1 min, 
and centrifuged for 5 min at 5,000 rpm. The supernatant was collected and an aliquot of 
100 µL was injected into the HPLC system for the assay of acitretin. A HPLC system that 
consisted of a LC-10Ai pump, SPD-10Ai UV-Vis detector, SIL-10Ai auto injector and 
SCL-10AVP system controller was used (Shimadzu, Japan). Separation of acitretin was 
performed on a reverse-phase column (ODS Hypersil, 5 µm, 250 × 4 mm, Hewlett 
Packard, Germany), which was protected by a precolumn filter (Rheodyne Inc., Cotati, 
CA) and a guard column (ODS-Hypersil, Hewlett Packard, Waldvronn, Germany). The 
detection was made at 340 nm. The mobile phase consisted of acetonitrile-methanol-2%-
ammonium acetate (45:25:30 v/v) and the flow rate was 1.2 ml/min. Under such 
chromatographic condition, acitretin was eluted at 5.9 min. Peak recording and 
integration were performed using Shimadzu CLASS-VP data management system. The 
limit of quantification (LOQ) for acitretin in rat plasma was determined to be 5 ng/mL. 
The in-between run coefficients of variation of acitretin were less than 5% at all 
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5.3.2 Measurement of the Total Concentration of Acitretin and its β-glucuronide  
         Conjugated Metabolite in Bile 
          The bile was analyzed for intact and total (intact plus conjugate) acitretin. The 
intact acitretin in bile (0.1 mL) was processed as described in the previous paragraph for 
the analysis of plasma. For the analysis of total acitretin in bile, an aliquot (200 µL) of the 
bile sample was incubated with β-glucuronidase, prior to the HPLC assay. Briefly, the β-
glucuronidase solution was freshly prepared by dissolving β-glucuronidase (Sigma type 
B-3) in saline. 200 µL of 0.2 M sodium acetate (pH = 5) was added to each of the bile 
sample, followed by 800U β-glucuronidase. The mixture was then incubated in a shaking 
water bath at 37°C for 24 h.  The control sample (incubated without enzyme) and the test 
sample (incubated with enzyme) were run concurrently. After incubation, the samples 
were cooled to room temperature and the acitretin concentration in the sample was 
determined by HPLC method described above. The difference in the concentration of 
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5.4 Preparation of Dosing Solutions 
          The HPBCD/acitretin complex solution for intravenous injection was prepared as 
follows: 100 mg of acitretin was suspended in 10 mL of phosphate buffer (pH = 9) 
containing 0.3 M HPBCD. The suspension was sonicated for 1 h and then shaken on a 
horizontal rotary shaker for 48 h at a speed of 400 rpm at ambient temperature. The 
suspension was finally filtered through a 0.45 µm disc filter (Whatman Ltd., Kent, UK). 
The clear solution was properly diluted, measured with HPLC to quantitate its acitretin 
concentration, and then stored in amber bottle well-protected from light at -20°C. The 
RMBCD/acitretin complex solution for oral administration was prepared in the same way 
as described above. The solubilities of acitretin at pH 9 in 0.3 M of HPBCD and RMBCD 
were found to be 1.02 and 2.74 mg/mL respectively. The intravenous and oral dosing 
solutions of cyclodextrin-based acitretin were then adjusted to 1.0 mg/ml and 1.5 mg/ml, 
respectively before administration.  The acitretin suspension was used as the control 
formulation for oral administration. This suspension was prepared by suspending acitretin 
in 1% (w/v) carboxymethyl cellulose sodium salt (CMC) (pH = 9) to obtain an acitretin 
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5.5 Animals  
         Adult male Sprague-Dawley rats (200-260 g) were obtained from the Laboratory 
Animal Center, National University of Singapore. The rats were housed separately in 
single cages and kept on a 12-h light/dark cycle. Food (standard mouse pellet) and water 
were provided ad libitum during experiment, unless otherwise stated. On the day before 
the pharmacokinetic study, the in-dwelling cannula was inserted into the jugular vein 
under anesthesia. Briefly, the fur around ventral right side of the neck was shaved. The 
skin was sterilized with 70% alcohol. An incision was made in skin, and the neck muscle 
was gently separated to expose the right jugular vein. A small cut was made on the vein 
by scissors, and a piece of PE-50 tubing (I.D. 0.58mm, O.D. 0.965mm, Clay Adam Brand, 
Beckon Dickison, Sparks, MD) was inserted and pushed to right atrium. The cannula was 
anchored with sutures and exteriorized through the skin at the back of the neck. The 
muscle and skin then was closed with suture. The blood flow was examined and the 
tubing was filled with heparinized (50 IU/ml) normal saline solution.  Intravenous doses 
were given and blood samples were collected via this cannula. 
 
         A total of six groups of rats were studied with 6 rats in each group. Rats in Groups 1, 
2 and 3 received a single intravenous dose of acitretin (2.5, 5 or 10 mg/kg, respectively) 
and aliquots of blood samples (~ 0.15 mL) in all these groups were collected at 0.25, 1, 2, 
3, 4, 5, 7, 9, 12, and 24 h after intravenous injection. Heparin (50U)-saline was used to 
flush the catheter after each intravenous injection and blood sampling. Blood samples 
were centrifuged at 5,000 rpm for 5 min; plasma samples were then collected, and kept 
frozen at -80°C until the HPLC assay. On the day of the experiment, the rats in Group 4 
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were lightly anesthetized with diethyl ether and the bile duct was cannulated according to 
the method of Wang and Reuning (1994). Briefly, a 2.5-cm ventral midline skin and 
abdominal muscle wall incision was made. The duodenum was gently retracted to reveal 
bile duct.  After placing the sutures, a small incision is made into the lumen of bile duct. 
A polyethylene catheter (PE 10, I.D. 0.28 mm, O.D. 0.61 mm) was inserted toward the 
liver (against the direction of bile flow). Bile was observed flowing into the cannula. The 
cannula was secured in place with suture. The rats were allowed to recover for half an 
hour and were allowed water and food ad libitum. After the single intravenous dose of 
acitretin (5 mg/kg), blood samples were collected at the same sampling intervals as for 
Groups 1-3. Total bile was collected from the entire 24-h study period at an interval of 1 
h from 0-12 h and an interval of 12-24 h after the intravenous injection. The bile samples 
were then kept at -80°C until analyzed. Each bile sample was subjected to two treatments: 
one was with β-glucuronidase incubation in order to determine the total concentration of 
acitretin, whereas the other was without incubation in order to determine the unchanged 
acitretin. Group 5 received a single oral dose of acitretin, which was suspended in 1% 
w/v carboxymethyl cellulose sodium salt (pH 9). Aliquots of blood samples (~ 0.15 mL) 
were collected at 0.5, 1, 2, 3, 4, 5, 7, 9, 12, and 24 h. For Group 6, acitretin was 
administered orally in the form of RMBCD/acitretin complex solution.  Blood samples (~ 
0.1 mL) were collected at 10, 20, and 40 min, and at 1, 1.5, 2, 3, 5, 7, 9, 12, and 24 h. To 
avoid the interference of food on the oral absorption of acitretin, all rats in Groups 5 and 
6 were fasted overnight before the pharmacokinetic study. The research adhered to the 
guidelines for the humane use of animals in scientific research.  
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5.6 Pharmacokinetic Analysis 
         All compartmental and non-compartmental pharmacokinetic parameters were 
estimated with the software program WinNonlin, version 1.0 (Scientific Consulting Inc., 
Lexington, KY). The area under the plasma concentration-time curve (AUC) in rats that 
received oral administration (Groups 5-6) was calculated by the trapezoidal rule while the 
AUC in rats that received intravenous dosing (Groups 1-4) was estimated through the 
same rule except taking logarithmic scale and extrapolating to infinity. Clearance (Cl) 
was calculated as Cl = Dose/AUC for oral dosing. The absolute bioavailability (F) values 
of acitretin in Groups 5 and 6 were calculated as follows: 
 
                     F = AUC (Group 5 or 6)/AUC (mean of Group 2) 
 
           Since a rapid distribution phase of acitretin was observed after intravenous dosing 
in all of the rats, pharmacokinetic parameters were generated by fitting the plasma 
concentration × time data to the classical two-compartment first-order open model (the 
model was supplied by WinNonlin version 1.0) using nonlinear least squares curve fitting 
as described previously (Lin et al., 2001). While in Group 6, the plasma concentration × 
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5.7 Statistical Analysis 
         Statistical analysis was conducted by using SPSS 11.0 (SPSS Inc. Chicago. IL). All 
experimental data were expressed as means ± standard deviations (SD). Statistical 
comparisons between Groups 1, 2 and 3 were performed using one-way analysis of 
variation (ANOVA) with the post hoc Tukey test. The plasma concentrations of acitretin 
of Groups 2 and 4 at the same time point and the AUC of the two groups were compared 
with two-tailed, independent-samples, t-test. The F values of Group 5 and Group 6 were 
also compared with two-tailed, independent-samples, t-test. A value of p < 0.05 was 
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5.8 Results 
5.8.1 Intravenous administration study 
         The plasma kinetic profiles of acitretin after intravenous administration are shown 
in Figure 5.8.1. As the kinetic profiles in the semi-logarithmic plots of acitretin plasma 
concentration × time were non-linear in all of the rats from Groups 1-3, the two-
compartment first order elimination model was applied. The pharmacokinetic parameters 
are listed in Table 5.8.1. These parameters were obtained by fitting the acitretin plasma 
data of individual rat to the two-compartment first order open model, except that AUC 
and Cl were estimated through the non-compartmental method.  
 
         After intravenous administration, the AUCs of acitretin in Groups 1, 2, and 3 (dose 
2.5, 5, and 10 mg/kg, respectively) were 4.41 ± 0.45, 8.20 ± 0.64, 17.28 ± 0.47 mg*h/L, 
respectively. The AUCs were found to be proportional to the doses. The clearance (Cl) in 
Groups 1, 2 and 3 were 0.57 ± 0.06, 0.62 ± 0.03, and 0.58 ± 0.02 L/h/kg, respectively. No 
statistically significant difference in Cl existed among these three groups (p > 0.05). 
There were also no statistically significant differences (p > 0.05) observed among these 
three groups in the volumes of distribution at steady state (Vss). Statistically significant 
differences (p < 0.05) were found for the elimination constants (K10), the distribution rate 
constants from the central compartment to the peripheral compartment (K12) and volumes 
of central compartment (Vc) between Group 1 and Group 3, but no statistically significant 
differences were found between Group 2 and Group 3 in these parameters. The terminal 
half-life (t1/2 (β)) of Group 3 was found to be considerably different from that of either 
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Figure 5.8.1 Pharmacokinetic profiles of acitretin after intravenous dosing with     
                     acitretin-HPBCD complex solution. Key: (○) 10 mg/kg; (□) 5 mg/kg; (∆) 
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Table 5.8.1 Pharmacokinetic parameters of acitretin after intravenous 
administration  
 
Parameter * Group 1 Group 2 Group 3 Group 4
Dose (mg/kg) 2.5 5 10 5
Vc (L/kg) 0.87±0.08 1.03±0.07 a 1.04±0.09 a 1.06±0.15
K10 (h-1) 0.69±0.06        0.62±0.08 0.55±0.05 a 0.66±0.13
K12 (h-1) 0.20±0.08 0.106±0.033 a 0.053±0.023 a 0.09±0.02
K21 (h-1) 0.08±0.02  0.094±0.032 0.045±0.020 b 0.08±0.04
t1/2 (K10) (h) 1.02±0.09       1.14±0.16 1.26±0.10 a 1.06±0.18
t1/2 (β) (h) 12.1±3.82 9.56±3.09 a 21.8±4.05 b 8.48±2.23
Vss (L/kg) 3.20±1.52      2.19±0.11      2.82±1.85 1.90±0.41
Cl (L/ h/kg) 0.57±0.06      0.62±0.04      0.58±0.02 0.67±0.04
AUC0-∞(ng·h/ml) 4411± 446     8203± 636    17282 ±467 7534±427
 
*Pharmacokinetic parameters are represented by mean ± S.D. (n = 6).  Rats in Group 4 
had the bile duct canulated, while rats in Group 1-3 had the bile duct intact. 
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5.8.2 Biliary excretion of acitretin 
        The kinetics of acitretin after intravenous administration in rats with (Group 4) and 
without (Group 2) bile-duct cannulation are shown in Figure 5.8.2. The parameters 
obtained from the intact (Group 2) or bile-duct cannulated rats (Group 4) are listed in 
Table 4.8.1. The cannulation of the bile-duct had no impact on Vc, as Vc in Group 4 
remained unchanged in comparison with Group 2 (1.06 ± 0.15 L/kg vs 1.03 ± 0.07 L/kg). 
Similarly, there was no statistically significant difference in the distribution rate constants 
from the peripheral compartment to the central compartment (K21) and from the central 
compartment to the peripheral compartment (K12) between Groups 2 and 4. However, 
bile-duct cannulation might have some impact on the terminal elimination of acitretin. 
Although no statistically significant difference (p > 0.05) was observed in total clearance 
and the terminal elimination rate constant (β) between Groups 2 and 4, these parameters 
tended to increase in bile-duct cannulated rats (Group 4) (0.621±0.035 L/kg·hr vs 
0.662±0.042 L/kg·hr; 0.078±0.023 hr-1 vs 0.084 ± 0.022 hr-1). Furthermore, the plasma 
acitretin concentrations in rats with bile-duct cannulated were significantly (p < 0.05) 
lower than those in normal rats at the fifth hour after intravenous administration. 
However, it is important to note that the concentration of acitretin at that time was only 
0.3% of the highest concentration. Therefore, the effect of enterohepatic circulation if any 
in the total pharmacokinetics of acitretin after intravenous dosing was insignificant. This 
hypothesis was supported by the observation of no significant difference in total AUC 
and clearance between Groups 2 and 4.  
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         The amount of acitretin glucuronide in bile samples was quantitatively determined 
by measuring the amount of acitretin released after treatment with β-glucuronidase. In 
order to assure the accuracy of the assay, control experiments were carried out to evaluate 
the completeness and specificity of the enzymatic hydrolysis reaction. The reaction was 
shown to be completed and to release an equimolar amount of acitretin. When bile 
samples were incubated but in the absence of enzyme, the metabolite profile was 
identical to that of untreated bile and no increase in the amount of acitretin was observed.  
 
         The bile excretion profiles of intact acitretin and its glucuronide conjugate were 
shown in Figure 5.8.3. Bile excretion played a very important role in the elimination of 
acitretin. However, only tiny amount of acitretin (0.46 ± 0.37% of the total dose) was 
excreted as intact acitretin. In contrast, 40.4 ± 10.3% of the administered acitretin was 





































Figure 5.8.2 Plasma concentration–time profiles of acitretin following intravenous 
administration of acitretin-HPBCD complex solution (5 mg/kg) to rats. 
Key: (□) Group 2 without; (○)Group 4 with bile-duct cannulation. Error bar 






















































Figure 5.8.3 Cumulative biliary excretion in percentage of the dose administered. 
Key:  (∆) unchanged acitretin; (□) total of unchanged acitretin and   
glucuronide conjugate after intravenous administration of acitretin (5 mg/kg) 
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5.8.3 Oral administration study 
          The kinetic profile of acitretin after oral dosing is shown in Figure 4.8.4 and Table 
5.8.2. The plasma drug concentration in rats (Group 5) after receiving an oral dose of 
acitretin suspended in 1% CMC increased slowly and with an average maximal 
concentration (Cmax) of 89.7 ± 34.7 ng/ml and an average time to Cmax of 4.67 ± 2.88 h. 
The kinetic profile of individual rat was highly irregular (individual figure not shown) 
and a secondary peak in plasma drug concentration was observed in most of the rats (5 of 
6 rats) roughly 7-9 hr after oral dosing. The irregular oral pharmacokinetic profile made 
the modeling difficult. Thus, only the non-compartmental estimation was executed. The 
average area under the curve (AUC) and absolute oral bioavailability (F) were 1055.3 ± 
469.6 ng·h/ml and 13.5 ± 6.0%, respectively. In summary, the oral absorption of acitretin 
in 1% CMC suspension (pH 9) was fairly poor and highly irregular. 
 
         The kinetic profile of RMBCD based acitretin was significantly different from that 
of the 1% CMC suspension. The plasma concentration of acitretin increased rapidly and 
reached Cmax (857.1 ± 114.3 ng/ml) within 1.5 h in all rats. After the maximal 
concentration, the drug concentration declined steadily and was well accorded to the two-
compartment first-order elimination model. No secondary peak point was observed in any 
of the rats. Obviously, acitretin was much better absorbed from the RMBCD/acitretin 
complex solution than from the acitretin suspension (Figure 5.8.4 and Table 5.8.2). The 
mean Cmax of acitretin observed in Group 6 (RMBCD-acitretin) was about 10 times 
higher than that observed in Group 5 (acitretin suspension) while mean values of AUC 
and F observed in Group 6 were about three times higher than those values observed in 
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Group 5. The difference in these kinetic parameters was highly statistically significant (p 
< 0.0001). Interestingly, the pharmacokinetic parameters in rats receiving RMBCD-
acitretin were much less variable than those in rats receiving acitretin suspended in 1% 
CMC. The coefficients of variation of Cmax, Tmax, and F were 38.7%, 61.6%, and 44.5%, 
respectively in Group 5; while the same values were 13.3%, 21.9%, and 17.1%, 
respectively in Group 6, indicating that RMBCD-based formulation of acitretin delivered 
more consistent oral absorption. In summary, the results obtained from the 
pharmacokinetic study of acitretin after oral administration clearly indicated that 
inclusion of acitretin into RMBCD could increase both the extent and the rate of its oral 






































Figure 5.8.4. Pharmacokinetics of acitretin after oral dose of 5 mg/kg of acitretin. 
Key: (□) acitretin-RMBCD complex solution; (∆) acitretin suspension. 



























Table 5.8.2 Pharmacokinetic parameters of acitretin after an oral dose of 5 mg/kg 
 
Parameter* RMBCD-acitretin complex solution Acitretin suspension
Tmax (h) 1.3 ± 0.3 4.7 ± 2.9 a
Cmax (ng/ml)                    857.1 ± 114.3 89.7 ± 34.7 b
AUC0-24 (ng·h/ml) 3175.3  ± 544.0 1055.3 ± 469.6 b
F (%) 40.5 ± 6.9   13.5 ± 6.0 b
Ka ( h-1) 1.6± 0.5                                N.D. 
 
*Pharmacokinetic parameters are represented by mean + S.D. (n = 6). a p < 0.05; b p < 
0.0001; N.D. is “unable to determine” 
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5.9 Discussion  
          The pharmacokinetic data of acitretin after intravenous administration was sparse 
because its poor aqueous solubility makes a parenteral dosage form difficult. Up to date, 
only several studies were carried out with micelle as an intravenous drug carrier 
(Brouwer and McNamara, 1989; McNamara and Blouin, 1990; Chien et al., 1992). 
Though no evidence showed that the micelle could change the kinetics of acitretin upon 
intravenous dosing, there is still the possibility for such a dosage form to alter its 
distribution and elimination profile. Thus, the intrinsic pharmacokinetics of acitretin 
remains unknown to date. Adjustment of pH in the preparation of intravenous dosage 
forms of various drugs with limited aqueous solubility, for example in pre-clinical 
pharmacokinetic studies of tretinoin and isotretinoin, which are the first generation 
retinoids, had been carried out with 0.3% NaOH (Shelley, 1982; El Mansouri, 1995). 
However, 0.3% NaOH did not fully solublize acitretin, a second generation retinoid (data 
not shown). Therefore, the prospect of formulating a parenteral formulation of acitretin 
solely by pH adjustment is not promising. The parenteral safety of HPBCD has been well 
documented through clinical practice and extensively reviewed. Also, it has been 
reported that HPBCD could greatly improve the aqueous solubility of acitretin (Loftsson 
et al., 1995) and the phase solubility study in Chapter III confirmed this result. Thus, the 
HPBCD-based formulation was adopted as the intravenous carrier for acitretin in the 
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           However, there is still the issue whether the kinetic data obtained with HPBCD-
based acitretin could closely mimic the intrinsic pharmacokinetics of acitretin. 
Fortunately, the binding affinity between acitretin and HPBCD was fairly weak according 
to the study in Chapter 4 and it is well known that no covalent bond is formed during the 
formation of inclusion complex (Loftsson and Brewster, 1996). As Stella (1999) and co-
workers suggested that after parenteral administration, the major driving force for 
dissociation of weakly to moderately bound drugs in the inclusion complex appears to be 
simple dilution. It has been noted that drug release from cyclodextrin complexes is rapid 
and quantitative in most cases; in aqueous solution, drug/cyclodextrin complexes are 
continually forming and dissociating with lifetimes in the range of milliseconds or less 
(Stella et al., 1999). Theoretically, such a short period of time should not change the drug 
pharmacokinetics. Upon intravenous administration, acitretin is expected to be rapidly 
and quantitatively released from HPBCD inclusion complex as the binding affinity 
between acitretin and HPBCD is weak. Furthermore, protein binding may also facilitate 
drug dissociation from cyclodextrin-drug complex (Frijlink et al., 1991; Stella et al., 
1999). Acitretin has been found to be extensively bound to plasma protein (Pilkington 
and Brogden, 1992), which would further facilitate drug dissociation from the 
cyclodextrin-drug complex. Hence once administered, acitretin would be rapidly released 
from the cyclodextrin inclusion complex and become well bound to the plasma proteins. 
Therefore, it is less possible for HPBCD to have a significant impact on the 
pharmacokinetics of acitretin upon intravenous administration and the data obtained with 
HPBCD-based formulation could sufficiently describe the full picture of the intrinsic 
kinetic profile of acitretin after intravenous administration. In fact, it has been reported 
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that HPBCD-based formulation of tretinoin did not change its pharmacokinetics with 
intravenous dosing (Lin et al., 2001). 
 
          In this study, the pharmacokinetics of acitretin after intravenous dosing with 
HPBCD-based acitretin was investigated and the clearance of acitretin was found to 
remain unchanged within a fairly broad dose range (2.5, 5, 10 mg/kg). This was in good 
accord with the clinical observation (Brindley, 1989). In psoriatic patients plasma 
concentrations of acitretin increased with ascending doses following one single 
administration of 25-100 mg acitretin and steady-state concentration of acitretin increased 
proportionally within a 10- to 50-mg dose range (Brindley, 1989). Linear elimination is a 
desirable pharmacokinetic property, as the drug level could be easily adjusted to its 
therapeutic level. Though the clearance of acitretin is dose-independent, several other 
pharmacokinetic parameters, e.g. Vc, t1/2 (K10), K10, K12, K21, and t1/2 (β) appeared to be 
related with dose in this study, as statistically significant differences were observed.  
However, a conclusion of dose-related properties of these pharmacokinetic parameters 
might be misleading. It is well known that the elimination half-life of acitretin is fairly 
long (over 50 hr in human) (Pilkington and Brogden, 1992). Unfortunately, the HPLC 
assay applied in the current study was not sensitive enough to determine its real terminal 
elimination, as the plasma acitretin level became undetectable 24 hours after dosing. 
Therefore, bi-exponential equation generated with the plasma drug concentration data 
obtained with such HPLC method might not describe the terminal elimination accurately 
and the terminal half-life (t1/2 (β)) estimated in the present study (12.06 ± 3.82, 9.56 ± 3.09, 
21.76±4.05 hr for Groups 1-3, respectively) is likely to be an underestimation of the true 
Chapter 5. Biopharmaceutics of cyclodextrin-based formulations of acitretin in SD rats 
 152
value. The plasma drug concentration data were attempted to be fitted into the three-
compartmental model. However, fitting to the three-compartment model gave 
consistently higher Akaike’s values and more importantly, very imprecise estimations of 
the parameters with very high % coefficients of variations. Therefore, the two-
compartment model was adopted for describing the pharmacokinetics of acitretin in the 
present study. The three-compartmental model might give better fitting and estimation of 
the parameters, if more plasma concentration data were obtained after 24 hour. Based on 
the study in human, it has been reported that it was unlikely to accurately determine the 
terminal elimination rate constant for acitretin from single dose data due to the lack of 
assay sensitivity at very low drug levels (Paravicini et al., 1984). The terminal phase 
becomes more evident after multiple dosing, where the terminal elimination half-life can 
be more accurately estimated (Brouwer and McNamara, 1989). In previous animal 
pharmacokinetic studies after single intravenous dosing, compartmental pharmacokinetic 
modeling was not executed and only non-compartmental method was applied in order to 
avoid such problem. 
 
         Although metabolic pathway and elimination of acitretin have been extensively 
studied and reviewed (Paravicini et al., 1981; Hanni, 1978), the precise extent of biliary 
excretion of acitretin has not been reported up to date. In the present study, it was found 
that the major fraction of acitretin is excreted in the bile as a conjugate (~ 40%); only 
trace amount (~ 0.5%) of the total dose existed in bile as intact acitretin. The data 
presented herein are consistent with former report that the primary route of elimination 
for the acitretin in the rat is via conjugation with glucuronic acid and excretion in the bile 
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(Hanni, 1978). The conjugation with glucuronic acid also plays an important role in 
elimination of other retinoids, e.g. tretinoin and isotretinoin (Meloche and Besner, 1985). 
Many compounds that have a carboxylic acid function (e.g. anti-inflammatory drugs) are 
metabolized to water-soluble glucuronide conjugates which are readily excreted in the 
bile (Lin et al., 1985; Singh et al., 1988). In the intestinal tract, the conjugates are 
hydrolyzed by β-glucuronidase, an enzyme produced mainly by intestinal 
microorganisms (Scheline, 1968). The re-absorption of excreted compounds from the 
intestines to systemic circulation results in the enterohepatic circulation of the drug. In 
the current study, we noticed that the plasma acitretin concentrations in rats with bile-
duct cannulation (Group 4) were significantly (p < 0.05) lower than those in normal rats 
(Group 2) 5 hours after intravenous administration. This phenomenon could be attributed 
to the re-absorption of acitretin through enterohepatic circulation. As the bile duct was 
cannulated in Group 4, the re-absorption of acitretin through enterohepatic circulation 
was disrupted, leading to a significant decline (p < 0.05) in plasma drug concentration 5 
hours after the intravenous dosing. However, the aqueous solubility of acitretin is very 
low that would prevent the effective re-absorption of the drug in the absence of 
cycodextrin through the enterohepatic circulation. Thus, the contribution of enterohepatic 
recycling on the pharmacokinetics of acitretin would be minimal.  
 
          Cyclodextrins are well known for their ability to improve the oral absorption of 
various drugs with limited water solubility. Orally administered cyclodextrins are 
practically nontoxic, because of lack of absorption through the gastrointestinal tract (Irie 
and Uekama, 1997). In the current study, it was found that RMBCD-based formulation of 
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acitretin could greatly enhance its oral absorption with roughly 10-fold increase in Cmax 
and 3-fold increase in absolute bioavailability. The improved oral absorption might be 
attributed to the increase in its aqueous solubility. It is generally regarded that the 
absorption of a drug from an oral dosage form into the general circulation involves 
delivery of the drug to its absorption site, getting the drug into solution, movement of the 
dissolved drug through the membranes of gastrointestinal tract, movement of the drug 
into the general circulation (Hoener and Benet, 1996). It is imperative, however, that the 
drug be in solution before it can be absorbed. For the drug with limited aqueous solubility, 
the dissolution of the drug will determine the rate and extent of availability of a drug 
from its dosage form (Hoener and Benet, 1996). Acitretin is highly lipophilic, although it 
is a carboxyl acid, and could not be fully solubilized by 0.3% NaOH (data not shown). 
Thus, its dissolution in gastric intestinal fluid could be problematic, resulting in a slow 
and incomplete absorption. In contrary, inclusion of acitretin into RMBCD increased its 
aqueous solubility and therefore overcome the dissolution problem, resulting in rapid and 
complete absorption.   
 
          The intra- and inter-patient variability in oral pharmacokinetics of acitretin has 
been observed. In the current study, the kinetic profile of acitretin after receiving oral 
acitretin suspension was highly irregular and variable. This was in good accord with the 
clinical observation. The variability in oral pharmacokinetics of acitretin could also be 
explained by its limited solubility. As the water solubility of acitretin is almost nil, its 
dissolution in gastric intestinal tract depended on the pH, fatty acid composition and the 
inherent bile salt solubilization capacity of the intestine. In rats receiving acitretin 
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suspension, a small variation of these factors could lead to a big difference in dissolution 
properties and subsequently in the plasma drug concentration. However, in rats receiving 
RMBCD-acitretin, as RMBCD could solublize acitretin, the impact of such factors 
became non-determinative. Thus, the oral kinetics in rats receiving RMBCD-acitretin was 
much less variable than that in rats receiving acitretin suspension.  
 
        It was found that there was a secondary peak at about 7-9 hours after dosing in the 
concentration versus time graph for rats given the acitretin suspension while such a 
phenomenon was not observed for the rats receiving RMBCD-acitretin. Similar double-
peak phenomenon has been observed for some other oral drugs (Bressolle et al., 1994; 
Mummaneni et al., 1995; Wang et al., 1999). Several mechanisms have been proposed to 
account for the phenomenon: enterohepatic recycling (Veng-Pedersen, 1980), 
discontinued or variable absorption along the gastrointestinal tract (Wagner, 1984), and 
variable gastric emptying (Oberle and Amidon, 1987). Enterohepatic recycling could be 
ruled out as the main cause of the secondary peak in the acitretin plasma concentration-
time curve, because this phenomenon did not appear after iv and oral administration of 
the acitretin-cyclodextrin complex solution. Variable gastric emptying might not be the 
reason either, since the two groups of rats were both administered with acitretin after 
fasting over night. Acitretin is a hydrophobic drug. The oral absorption of acitretin from 
suspension solution would be a dissolution rate-limited process. Any variation in pH, bile 
concentration or other physiological factors that affect the dissolution of acitretin in 
gastrointestinal fluid would lead to variable oral absorption of acitretin, causing the 
appearance of the secondary peak in the acitretin plasma concentration-time profile after 
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oral administration of the suspension solution. A similar phenomenon was not observed 
in the rats receiving the acitretin-RMBCD solution, in which the solubility of acitretin 
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5.10 Conclusion 
          In this study, the biopharmaceutical properties of the CD-based formulations of 
acitretin were tested in Sprague-Dawley rats after intravenous or oral administrations. 
The pharmacokinetic data obtained with CD-based acitretin after intravenous 
administration closely mimic the intrinsic pharmacokinetics of acitretin. It was also found 
that inclusion of acitretin into RMBCD could dramatically improve its oral 
bioavailability and decrease the variation of its oral pharmacokinetics. Thus, a CD-based 
oral formulation of acitretin would provide beneficial effect for its clinical application. 
However, this postulation warrants further investigation. 
 
 








          Retinoids have been studied intensively for their effects on melanoma cells. 
However, there is no systematic in vivo study comparing the effects of different retinoids 
on the metastases of melanoma. In this thesis, five retinoids, ATRA, 9-cis-RA, 13-cis-RA, 
etretinate, and acitretin, were evaluated on their efficacies on the growth and inhibition of 
invasion of murine melanoma cell line – B16F10 cell line. The combining effects of these 
retinoinds with the respective CDDP and 5-FU were also evaluated.  It was found that 
ATRA, 9-cis-RA and 13-cis-RA significantly inhibited the growth and invasion of 
B16F10 cells in vitro. At the same time, they reduce the IC50 of CDDP. Based on the data 
from these in vitro studies, the effects of ATRA, 9-cis-RA, 13-cis-RA on experimental 
lung metastases in vivo and the combining effects of retinoid and CDDP on lung 
metastases of melanoma in mice were also investigated. The results showed that 13-cis-
RA suppressed the metastasis of B16F10 mouse melanoma cells in experimental lung 
metastasis model and combination treatment of CDDP and 13-cis-RA could suppress the 
primary tumor growth and lung metastasis of mouse melanoma cells with moderate 
toxicity. ATRA showed more potent efficacy and also greater toxicity, while 9-cis-RA 
had lower efficacy, compared to 13-cis-RA. This indicates that 13-cis-RA is suitable for 
single and combination treatments for malignant melanoma. However, further clinical 
trial has to be performed to confirm this hypothesis. Mechanisms of the effects of 
retinoids on the metastatic melanoma could be complicated. From the preliminary 
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findings in this thesis, retinoids appear to inhibit melanoma cell invasion through 
reducing MMP-9 levels in the cells. However, more experiments have to be done before a 
conclusion can be made.  
 
         Retinoids are promising as anti-cancer drugs that are worthy of further development 
because retinoids are highly insoluble in water, it would be desirable to develop 
formulations of retinoids with improved biopharmaceutical properties. In this thesis, CD-
based formulations of 13-cis-RA and acitretin were developed, which could dramatically 
improve the solubility and photostability of these drugs. Physicochemical 
characterization of these formulations confirmed the formation of inclusion complexes 
between the drug and the respective CD. It was found that the binding constant between 
the drug and the CD was affected by the pH value and the type of CD. Molecular 
modeling was performed and the energy scores obtained from molecular modeling 
showed a positive correlation with the binding constants. Thus, computational molecular 
modeling could be applied to predict the binding and protecting ability of various CDs.  
    
         Information on the pharmacokinetic properties of intravenous acitretin was limited 
due to its poor aqueous solubility. Since HPBCD is safe for parenteral administration, 
HPBCD was adopted as the intravenous carrier for acitretin to elucidate its 
pharmacokinetic property. Pharmacokinetic studies of this newly developed formulation 
in Sprague-Dawley rats indicated that acitretin offers a linear pharmacokinetic profile, 
which is a desirable property, as the drug level could be easily adjusted to its therapeutic 
level.  In this thesis, it was also found that RMBCD based formulation of acitretin 
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improved its oral bioavailability and decreased the variation of its oral pharmacokinetics. 
Thus, a CD-based formulation of acitretin could provide beneficial effect for oral 
application. Since inclusion of acitretin into CDs led to an improvement in its 
photostability, CD-based formulations of acitretin could also be useful for topical, 
dermatological applications.  
 
         In conclusion, retinoids are promising in the treatment of metastatic melanoma. The 
cyclodextrin-based formulations of retinoids could potentially offer advantages of 
improved efficacies over the existing formulations.  However, these postulations have to 
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6.2 Future studies 
       Since CD could increase the solubility and photo-stability of acitretin and 13-cis-RA, 
it is possible that CD could be used for topical formulations or transdermal delivery of 
these drugs to improve their clinical efficacy. Ideal characteristics of a drug for 
transportation across the skin include low interaction with the skin and no metabolism by 
the skin. Thus, the influence of CD on the in vitro permeation and skin metabolism of 
acitretin and 13-cis-RA sould be further investigated before their application.  
 
       Since CD based formulations of acitretin showed some beneficial results in Sprague-
Dawley rats after intravenous and oral administration, CD-based formulation of 13-cis-
RA could also have some advantages over current formulations. This postulation needs to 
be confirmed with a pharmacokinetic study. In addition, biopharmaceutical properties of 
these CD-based formulations and their impact on clinical applications have to be 
investigated.  
 
          In the present study, 13-cis-RA was found to be effective for inhibiting cell 
proliferation and invasion of B16-F10 melanoma cells in vitro and for suppressing lung 
metastasis of B16-F10 cells in vivo. However, the mechanisms of these effects remain 
unknown. Evidence suggests that proteolytic enzyme systems are important for 
melanoma progression (Ferrier et al., 1998). In human and murine melanoma cell lines 
increased expression of MMP-2, MT1-MMP, and MMP-9 were shown to correlate with 
an invasive phenotype (Kurschat et al., 1999; Hofmann et al., 1999; Hofmann et al., 
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2000). In this thesis, ATRA and 13-cis-RA were found to decrease MMP-9 expression in 
B16F10 cells in vitro. Further study should investigate their effects on the expression of 
other proteolytic enzymes in vitro and in vivo.  
 
          In the recent years, several new retinoids have been synthesized to improve the 
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